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ABSTRACT 
Protein aggregation has been identified as the cause of several 
neurodegenerative disorders such as Alzheimer’s Disease (AD), Parkinson’s Disease 
(PD) and Familial Amyloid Polyneuropathy (FAP). AD is characterized by the 
extracellular deposition of amyloid-β (Aβ) aggregates mainly in the hippocampal region 
of the brain. Aβ degradation is one of the promising therapeutic targets in AD. Among 
the several Aβ-degrading enzymes, the metalloprotease transthyretin (TTR) was shown 
to be a good candidate with encouraging in vitro results. The Aβ cleavage by TTR was 
shown to occur in multiple positions, resulting in the production of peptides with lower 
amyloidogenic potential. Moreover, data from our group demonstrated that TTR WT, but 
not the proteolytically inactive form of the protein, is capable of interfering with Aβ 
fibrillization by both inhibiting and disrupting fibril formation. In this work, we aimed to 
further dissect the role of TTR proteolytic activity in AD using both cell based assays and 
in vivo models. We used the TTR proteolytic inactive mutant and compared its 
neuroprotective effect with TTR WT by: i) analyzing the effect on Aβ clearance and 
neurotoxicity by using N2A-APPSwe cells and hippocampal neurons, respectively; and 
ii) assessing its neuroprotective effect in vivo using mice and zebrafish as animal models. 
Using the cell based assays, we verified that TTR proteolytic activity is maintained under 
physiological conditions and is required for TTR neuroprotective effect in AD by 
increasing Aβ clearance and decreasing neurotoxicity. The relevance of TTR proteolytic 
activity in vivo could not be clarified by the use of TTR intracerebral administration in a 
mouse model of AD, what was mainly related with the high variability within animals from 
the same experimental groups. Using zebrafish as another in vivo model, we were able 
to recapitulate a previously reported methodology using Veins zebrafish (that express 
GFP in the gut vasculature) treated with Aβ, that will be used in the future to further 
address TTR proteolytic activity in an in vivo system.  
Damage to the neuronal cytoskeleton has been observed in several 
neurodegenerative disorders. Aiming at determining whether neuronal cytoskeleton 
damage is a common pathogenic mechanism induced by protein aggregates in unrelated 
neurodegenerative disorders, in this work we used the growth cone morphology of 
hippocampal neurons (which has a distinctive distribution of both microtubules and actin 
filaments) as a fine tool to understand the effect of different prone-to-aggregate proteins 
in the neuronal cytoskeleton of hippocampal neurons. The following species were 
analyzed: i) Aβ oligomers (the pathogenic protein in AD), untreated or treated with TTR, 
to determine whether TTR reverts cytoskeleton defects induced by Aβ oligomers; ii) α-
synuclein in different aggregations stages (the pathogenic protein in PD); and iii) TTR 
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amyloidogenic mutants (the pathogenic protein in FAP). In AD, several studies have 
demonstrated that the neuronal cytoskeleton is also one of the targets of Aβ oligomers-
induced neurodegeneration. Therefore, we incubated hippocampal neurons with Aβ 
oligomers and verified that the toxic species increased the number of dystrophic growth 
cones; however TTR WT, shown to have a neuroprotective effect in AD, was unable to 
rescue this phenotype. We also analyzed whether α-synuclein induces similar effects in 
the neuronal cytoskeleton as the ones observed with Aβ oligomers. We treated 
hippocampal neurons with α-synuclein at different aggregation states. Although a 
tendency to an increase in the percentage of dystrophic growth cones was observed with 
the treatment of the different α-synuclein species, no statistical differences were found. 
We also tested the effect of TTR variants that are associated with FAP in the growth 
cone morphology of hippocampal neurons. Although previous data from our group 
showed that TTR oligomers are able to induce growth cone morphology defects in dorsal 
root ganglia neurons, similar effects were not observed in hippocampal neurons. In the 
CNS neurons we observed a tendency to a decrease in the percentage of dystrophic 
growth cones after treatment with either TTR WT or TTRL55P, although not statistical 
significant, while TTR V30M has no effect. In conclusion, these results show that further 
studies should be conducted to unravel the effect of prone-to-aggregate proteins in the 
neuronal cytoskeleton. This approach would be crucial to determine whether common 
therapeutic approaches targeting the cytoskeleton would be a valuable strategy for 
unrelated neurodegenerative disorders caused by protein aggregation. 
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RESUMO 
A causa de várias doenças neurodegenerativas, como a doença de Alzheimer 
(AD), de Parkinson (PD) e a Polineuropatia amiloidótica familiar (PAF) tem vindo a ser 
relacionada com a agregação de proteínas. A AD é caracterizada pela deposição de 
agregados de β-amilóide (Aβ) extracelulares, maioritariamente na região do hipocampo. 
Um alvo promissor para o tratamento de AD é a degradação de Aβ. Entre as várias 
enzimas que o fazem, a metaloprotease transtirretina (TTR) foi identificada por ensaios 
in vitro como um bom candidato. A clivagem de Aβ pela TTR ocorre em múltiplas 
posições, resultando na produção de péptidos com baixo potencial amiloidogénico. Para 
além disso, resultados obtidos no nosso grupo demonstram que a TTR wild-type (WT) 
é capaz de interferir com a fibrilização por inibir e desregular a formação de fibras. A 
forma proteolicamente inactiva da TTR já não é capaz de interferir neste processo. 
Neste trabalho, o objectivo foi dissecar o papel da actividade proteolítica da TTR em AD 
usando tanto ensaios celulares como modelos in vivo. Para tal, usamos a forma mutada 
de TTR (proteoliticamente inactiva) e comparamos o efeito neuroprotector com o da TTR 
WT ao: i) analizar o efeito na remoção de Aβ e na neurotoxicidade usando células N2A-
APPSwe e neurónios do hipocampo, respectivamente; e  ii) aferir o efeito neuroprotector 
in vivo usando ratinhos e zebrafish como modelos animal. Com os ensaios celulares, 
nós verificámos que a actividade proteolítica da TTR é mantida em condições 
fisiológicas e é requerida para o efeito neuroprotector de TTR em AD pelo aumento da 
remoção de Aβ e diminuição da neurotoxicidade. A relevância da actividade proteolítica 
da TTR in vivo não pôde ser clarificada pelo uso de injecções intercerebrais de TTR num 
modelo de AD em ratinho, devido à alta variabilidade entre animais dentro do mesmo 
grupo experimental. Usando zebrafish como modelo in vivo, fomos capazes de 
recapitular uma metodologia previamente descrita com Veins zebrafish (que expressam 
GFP na vasculatura do tracto gastrointestinal) tratados com Aβ que serão usados no 
futuro para analisar a actividade proteolítica da TTR num sistema in vivo.  
Em várias doenças neurodegenerativas têm sido verificados danos no 
citoesqueleto neuronal. Com o objectivo de determinar se esse dano é um mecanismo 
patogénico comum induzido por agregados proteicos em doenças neurodegenerativas 
não relacionadas usámos, neste trabalho, a morfologia do cone de crescimento de 
neurónios do hipocampo (que têm uma distribuição distinta em microtúbulos e 
filamentos de actina) como uma ferramenta para compreender o efeito de diferentes 
proteínas com capacidade de agregação no citoesqueleto neuronal dos neurónios do 
hipocampo. As seguintes espécies foram utilizadas: i) oligómeros de Aβ (a proteína 
patogénica em AD), não tratados ou tratados com TTR, para determinar se a TTR 
                                                                                                                                            
vi 
 
reverte os defeitos no citoesqueleto induzidos pelos oligómeros de Aβ; ii) α-sinucleína 
em diferentes estados de agregação (a proteína patogénica em PD); e iii) mutantes 
amiloidogénicos de TTR (a proteína patogénica de FAP). Diferentes estudos 
demonstraram que em AD o citoesqueleto neuronal é alvo de neurodegeneração 
induzida por oligómeros Aβ. Assim, nós incubámos neurónios do hipocampo com 
oligómeros Aβ e verificámos que as espécies tóxicas aumentaram o número de cones 
de crescimento distróficos; no entanto, a TTR WT, que tem um efeito neuroprotector em 
AD, não foi capaz de reverter este fenótipo. Também analisámos se a α-sinucleína induz 
efeitos semelhantes no citoesqueleto neuronal aos observados com oligómeros de Aβ. 
Assim, neurónios do hipocampo foram tratados com α-sinucleína em diferentes estados 
de agregação. Apesar de haver uma tendência para aumentar a percentagem de cones 
de crescimento distróficos com o tratamento de diferentes espécies de α-sinucleína, 
diferenças estatisticamente significativas não foram encontradas. Também testámos o 
efeito das variantes de TTR que estão associadas com FAP na morfologia do cone de 
crescimento em neurónios do hipocampo. Apesar de dados do nosso grupo 
demonstrarem que os oligómeros TTR são capazes de induzir defeitos na morfologia do 
cone de crescimento em neurónios dos ganglios dorsais, efeitos semelhantes não foram 
detectados nos neurónios do hipocampo. Em neurónios do sistema nervoso central 
observamos uma tendência para diminuir a percentagem de cones de crescimento 
distróficos após o tratamento com TTR WT ou com TTR L55P, apesar de não ser 
estatisticamente significativo, enquanto TTR V30M não tem efeito. Para concluir, estes 
resultados mostram que mais estudos devem ser conduzidos para determinar o efeito 
de proteínas com capacidade de agregação no citoesqueleto neuronal. Esta abordagem 
pode ser crucial para determinar se as abordagens terapêuticas comuns que têm como 
alvo o citoesqueleto podem ser uma estratégia valiosa para doenças 
neurodegenerativas não relacionadas causadas por agregação de proteínas.  
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1. TRANSTHYRETIN 
Transthyretin (TTR) is a homotetrameric protein named after its first identified 
functions: the transport of circulating thyroid hormones (Woeber and Ingbar 1968) and of 
retinol through retinol-binding protein (RBP) (Goodman 1987). TTR is mainly synthesized 
in the liver and the choroid plexus of the brain which constitute the source of TTR in the 
plasma and the cerebrospinal fluid, respectively (Dickson, Howlett et al. 1985). TTR is also 
known for its role on familial amyloid polyneuropathy (FAP), a neurodegenerative disorder 
in which mutated TTR accumulates as amyloid fibrils particularly in the peripheral nervous 
system (PNS) (Saraiva, Magalhaes et al. 2012). 
1.1. ttr gene: structure, expression and evolution 
The ttr gene is a single copy-gene situated in chromosome 18 in humans 
(Whitehead, Skinner et al. 1984) and rats (Remmers, Goldmuntz et al. 1993), and in 
chromosome 4 in mice (Qiu, Shimada et al. 1992), being composed of 4 exons and 3 
introns. Although the gene length varies between species (from 6.8kb in humans to 7.3kb 
in rats), it presents three highly conserved regions: the entire sequence of exons, the 
5´proximal region and the flanking region of the exon-intron borders. Exon 1 codes for 20 
amino acids long signal peptide and the first three residues of the mature protein; exon 2 
encodes for amino acid residues 4-47; exon 3 for amino acid residues 48-92 and, finally, 
exon 4 codes for amino acid residues 93-127. The introns have 934, 2090 and 3308bp, 
respectively, and display GT/AG splicing consensus sequences (Sasaki, Yoshioka et al. 
1985). The pro-monomer is composed by 127 amino acids plus the signal peptide in the 
N-terminal region, which is removed in the endoplasmic reticulum, resulting in the native 
monomer (Soprano, Herbert et al. 1985).  
TTR is majorly expressed in the liver and in the epithelial cells of the choroid plexus 
of the brain and its pattern of gene expression is well characterized in numerous species, 
namely rat (Dickson, Aldred et al. 1985), human (Dickson and Schreiber 1986), sheep 
(Schreiber, Aldred et al. 1990), chicken (Southwell, Duan et al. 1991) and pig (Duan, 
Richardson et al. 1995). In humans, ttr expression starts in the tela choroidea and then in 
the liver (Harms, Tu et al. 1991, Richardson, Bradley et al. 1994) and it is also expressed 
in human placenta, eye and intestine (Loughna, Bennett et al. 1995, Schreiber and 
Richardson 1997, Getz, Kennedy et al. 1999).  In rats, ttr expression occurs since early 
embryogenesis and is gradually limited to the liver and the choroid plexus during the last 
phases of embryogenesis and is preserved during adult life. In adult rats, TTR is also 
expressed in the eye, heart, pancreas, skeletal muscle, spleen and stomach (Soprano, 
Herbert et al. 1985, Power, Elias et al. 2000). During vertebrate evolution, ttr expression 
                                                                                                                                            
4 
 
has changed considerably: while in fish it is found in the liver during development 
(Richardson, Monk et al. 2005), in reptiles it is expressed only in the choroid plexus of 
adult lizards (Achen, Duan et al. 1993). The preservation of ttr expression in the choroid 
plexus from reptiles to mammals during life suggests a fundamental role for TTR in the 
brain biology.  
1.2. TTR structure 
TTR is a homotetrameric protein composed of identical subunits of 127 amino acid 
residues each of approximately 14kDa (Kanda, Goodman et al. 1974). Each monomer is 
composed by eight β-chains that are organized as two parallel sheets of four strands, 
acquiring a beta sandwich conformation, and a very short α-helix. Two monomers interact 
through an extensive hydrogen bond along strands forming a dimer. Two dimers associate 
and form a tetramer creating a hydrophobic channel that goes through the protein (figure 
1). This originates two symmetrical binding sites that are able to accommodate two 
thyroxine (T4) molecules. Furthermore, TTR binds one RBP molecule and its binding sites 
are located at the surface of the molecule in a region involving interactions between both 
TTR dimers. The formation of the retinol-RBP-TTR complex stabilizes the TTR tetramer 
(Saraiva, Magalhaes et al. 2012).  
 
Figure 1 – Structure of TTR tetramer. PDB entry 1F41. 
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1.3. TTR metabolism 
Plasma-circulating TTR levels range from 170 to 420ug/mL while in the brain its 
concentration ranges from 5 to 20ug/mL (Vatassery, Quach et al. 1991) and represents 
20% of the total CSF proteins (Weisner and Roethig 1983).  
In humans, the biological half-life of TTR is about 2-3 days (Socolow, Woeber et 
al. 1965), while in rats it is 29 hours (Dickson, Howlett et al. 1982). The major degradation 
sites of TTR in rats are the liver, kidney, muscle and skin, although other sites have been 
reported namely the testis, kidneys, adipose tissue and gastrointestinal tract. Furthermore, 
both plasma and CSF TTR are metabolized in the same degradation sites and TTR 
degradation is not present in the nervous system (Makover, Moriwaki et al. 1988).  
Although TTR internalization by some tissues and cell types has been suggested, 
these mechanisms have not yet been fully discovered. In the kidneys and dorsal root 
ganglia (DRG), TTR is internalized by via megalin (Sousa, Norden et al. 2000, Fleming, 
Mar et al. 2009) and, in the liver, its internalization is mediated by an unknown receptor 
which is an associated protein (RAP)-sensitive receptor (Sousa and Saraiva 2001). 
1.4. TTR amyloidogenic variants 
TTR is known as one of the many proteins which acquire a misfolded conformation 
and undergo aggregation in vivo. Over one hundred TTR mutations have been described 
so far (Rowczenio and Wechalekar 2015). All mutations, except a single aminoacid 
deletion at position 122, arise from point mutations in the polypeptide chain (Saraiva 
2001). Most amyloidogenic variants of TTR are associated with neuropathies, but other 
conditions have also been described such as cardiomyopathy (Saraiva, Sherman et al. 
1990), carpal tunnel syndrome (Izumoto, Younger et al. 1992), vitreous TTR deposition 
(Zolyomi, Benson et al. 1998) and leptomeningeal involvement (Petersen, Goren et al. 
1997). TTR wild-type (WT) has also propensity for aggregation in vivo. Systemic senile 
amyloidosis, also named senile cardiac amyloidosis, is a highly prevalent late age of onset 
disease that typically affects elderly men (over 70 years) (Rapezzi, Quarta et al. 2010), 
characterized by the deposition of TTR WT fibrils specifically in the heart (Westermark, 
Sletten et al. 1990, Rapezzi, Quarta et al. 2010).  
The disease-associated TTR mutations decrease the stability of the tetramer or 
the monomer or both. Therefore, TTR amyloidogenic potential is governed by the extent 
of protein stabilization (Johnson, Connelly et al. 2012). In the TTR amyloidogenic cascade, 
the tetramer dissociates into the natively folded monomer which subsequently undergoes 
denaturation. The unfolded monomers aggregate very efficiently into a variety of 
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aggregate morphologies, including oligomers, non-fibrillar aggregates and amyloid fibrils 
(figure 2) (Johnson, Connelly et al. 2012). 
 
Figure 2 - TTR amyloidogenic cascade. The TTR tetramer dissociates into monomers which undergo 
denaturation, becoming an aggregation-prone amyloidogenic intermediate. Adapted from (Johnson, Connelly 
et al. 2012) 
The most common amyloidogenic TTR mutation is a substitution of a methionine 
for a valine at position 30 (TTR V30M) that is associated with FAP (Saraiva, Birken et al. 
1984) (see section 3.2.3). Other aggressive amyloidogenic variants such as TTR 
Leu55Pro (TTR L55P) were also described. TTR L55P is a highly amyloidogenic variant 
that induces a progressive form of neuropathy. Biochemical studies showed that this 
mutant presents decreased tetramer stability (McCutchen, Colon et al. 1993, Lashuel, Lai 
et al. 1998) due to alterations in the dimer-dimer contact regions (Sebastiao, Saraiva et 
al. 1998). Both these mutations were shown to destabilize the tetramer, generating 
partially unfolded monomers that have a high tendency for aggregation (Quintas, Vaz et 
al. 2001). Although some cases of homozygous individuals were described (Skare, Yazici 
et al. 1990), most carriers are heterozygous for the amyloidogenic TTR variants. For 
instance, double mutant individuals carrying the heterozygous V30M/T119M variants were 
identified with a less severe form of the disease, suggesting that T119M acts as a 
protective mutation (Alves, Altland et al. 1997).  
1.5. TTR physiological functions 
1.5.1. Transport of T4 and retinol 
The most acknowledge functions for TTR are the transport of thyroid hormones 
like T4 and vitamin A (retinol), in the latter case through binding to the RBP. In the human 
plasma, almost all T4 is bound to plasma proteins, namely T4-binding globulin (70%), TTR 
(15%) and albumin (10%) and some lipoproteins. In mice, TTR is the major T4 carrier, 
transporting 50% of total T4 (Hagen and Solberg 1974). TTR was proposed as being 
involved in thyroid hormone homeostasis and hormone delivery. However, the first studies 
regarding this interaction demonstrated that although the plasma levels of free T4 of TTR 
knockout (KO) mice were decreased, the liver and kidney of these mice didn’t show 
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differences in T4 levels (Palha, Episkopou et al. 1994, Palha, Hays et al. 1997). 
Furthermore, the absence of TTR did not alter the distribution of T4 in the brain. These 
results suggest that despite the fact that TTR is a transporter of T4, its absence doesn’t 
affect the normal thyroid hormone function. 
In the serum, retinol circulates bound to RBP and TTR, creating a complex that 
allows the delivery of retinol to tissues. Studies using TTR KO mice showed the existence 
of decreased levels of plasma retinol and RBP when comparing with WT mice (Episkopou, 
Maeda et al. 1993). However no differences were found in the tissue levels of total retinol 
between WT and TTR KO mice, with TTR KO mice lacking symptoms of vitamin A 
deficiency (Episkopou, Maeda et al. 1993, van Bennekum, Wei et al. 2001). The reduced 
levels of plasma RBP-retinol complex in TTR KO animals were related to an increased 
renal filtration, suggesting that TTR prevents RBP-retinol loss through renal filtration (van 
Bennekum, Wei et al. 2001). 
1.5.2. TTR as a nerve regeneration enhancer 
Trying to understand the preferential deposition of TTR in the PNS of FAP patients, 
several reports have assessed a role for TTR in the biology of the nervous system. In this 
respect, TTR was shown to enhance nerve regeneration (Fleming, Saraiva et al. 2007). 
TTR KO mice showed a decreased regeneration capacity after sciatic nerve crush when 
compared to WT littermates (Fleming, Saraiva et al. 2007). Transgenic TTR KO mice 
expressing TTR in neurons showed a rescue in the phenotype, strengthening that TTR is 
responsible for the enhancement of nerve regeneration (Fleming, Mar et al. 2009). In vitro, 
the same effect was observed as neurite outgrowth was decreased in primary cultures of 
DRG neurons from TTR KO mice, what might explain the impaired regenerative capacity 
of TTR KO mice (Fleming, Saraiva et al. 2007). It was also shown that TTR KO axons 
present a compromised retrograde transport what might account for the delayed 
regenerative capacity of TTR KO mice and decreased neurite outgrowth in the absence 
of TTR (Fleming, Mar et al. 2009). 
1.5.3. TTR as a novel protease 
In the plasma, a fraction of TTR is carried in high density lipoproteins through 
binding to apolipoprotein A-I (apoA-I), its major protein component. This interaction was 
investigated and TTR was found to be a novel plasma protease which is able to cleave 
the C-terminus of apoA-I (Liz, Faro et al. 2004). The relevance of apoA-I cleavage by TTR 
was determined; upon TTR cleavage, high-density lipoproteins display a reduced capacity 
to promote cholesterol efflux and cleaved apoA-I displays increased amyloidogenicity, 
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suggesting that TTR might impact in the development of atherosclerosis (Liz, Gomes et 
al. 2007).  
TTR proteolysis was also shown to impact on nervous system biology. In vitro work 
showed that TTR is able to cleave neuropeptide Y and that TTR proteolytic activity is 
necessary for its ability to enhance neurite outgrowth, suggesting the existence of 
additional TTR substrates in the nervous system (Liz, Fleming et al. 2009). The catalytic 
machinery behind the proteolytic activity of TTR was also revealed. The analysis of three-
dimensional structures of TTR complexed with Zn2+ and site-directed mutagenesis of 
selected amino acids confirmed that TTR is a metallopeptidase with His88, His90 and Glu92 
being the residues constituting the active site (figure 3) (Liz, Leite et al. 2012). This finding 
not only strengthens the establishment of TTR as a novel protease but also provides the 
possibility to modulate the proteolytic activity in order to analyze its relevance in both 
physiological and pathological conditions. 
 
 
Figure 3 - Structure of TTR active site. In cyan and dark blue are represented two different TTR monomers. 
The metallic ion zinc is linked by His88 and His90 and Glu92 is contacting with a water molecule. A second 
Zn2+ binding site consists of Glu72, His31 and Asp74. Glu89 and Thr96 of a second monomer contact by a 
hydrogen bond which is also in contact with His88. Attractive forces are showed in dashed lines. Adapted 
from: (Liz, Leite et al. 2012) 
1.6. TTR is neuroprotective in Alzheimer’s Disease 
TTR and Amyloid-β (Aβ) peptide interaction has been address by many groups 
since the CSF and plasma TTR levels of Alzheimer’s disease (AD) patients are decreased, 
proposing a neuroprotective action of TTR in AD (Riisoen 1988, Hansson, Andreasson et 
al. 2009, Ribeiro, Santana et al. 2012). The ability of TTR synthesized by the choroid 
plexus and secreted into the CSF to interact and impact on Aβ levels, aggregation state 
and/or toxicity has been questioned since Aβ is mainly present in the hippocampus and 
cortex. Therefore, the presence of TTR in brain areas other than its site of synthesis and 
secretion has been subject of study. Although TTR expression was demonstrated in the 
hippocampus of both AD patients and AD mice models (Schwarzman and Goldgaber 
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1996, Stein, Anders et al. 2004, Li, Masliah et al. 2011) and was also verified in vitro using  
SH- SY5Y cells (Kerridge, Belyaev et al. 2014, Wang, Cattaneo et al. 2014), a study using 
a mouse model with compromised heat-shock response showed that, in situations of injury 
such as ischemia, TTR is present in the brain, but it is derived from CSF-TTR (Santos, 
Fernandes et al. 2010). Thus, there is still debate on whether or not TTR is synthesized 
by neurons. Nevertheless, the referred studies support the importance of TTR in AD, 
reinforcing the need for a better understanding of this interaction. 
TTR is able to sequester Aβ, thereby preventing amyloid formation and toxicity in 
vitro (Schwarzman, Gregori et al. 1994). More recently, it was shown that TTR protective 
capacity is related to its binding to toxic/pretoxic Aβ aggregates in both intracellular and 
extracellular environment in a chaperone-like manner (Buxbaum, Ye et al. 2008). Further 
studies revealed that the inhibition and disruption of Aβ fibrils by TTR was the possible 
mechanism behind the protective role of this protein, since TTR binds to soluble, 
oligomeric and fibrillar Aβ with similar affinities and is capable of interfering with Aβ 
fibrillization (Costa, Goncalves et al. 2008).  
The nature of TTR/Aβ interaction was further investigated and TTR was found to 
be able to cleave Aβ in vitro in multiple positions which are also cleavage sites for other 
Aβ degrading enzymes. The proteolytic activity of TTR over Aβ generates peptides with 
lower amyloidogenic potential than the full length counterpart, suggesting that TTR 
contributes to its clearance (Costa, Ferreira-da-Silva et al. 2008). Nevertheless, TTR 
cleavage of Aβ was only demonstrated in vitro by SDS-PAGE using the two purified 
proteins, thus further studies should address the ability of TTR to cleave Aβ in a 
physiological environment. 
 
2. ALZHEIMER’S DISEASE 
AD is the most common form of dementia representing 60-70% of all cases and is 
increased among people over 65 years old. AD is a progressive neurodegenerative 
disorder of the central nervous system (CNS) characterized by the gradual decline in 
memory, thinking, language and learning capacity, ultimately leading to death (Duthey 
2013). Clinically, AD can be divided into three different stages: preclinical AD, mild 
cognitive impairment due to AD and dementia due to AD. Based on its age of onset, AD 
is classified into early onset AD (EOAD) and late onset AD (LOAD). The most common 
form of AD (~95% of all cases) is LOAD in which patients present an age at onset later 
than 65 years. EOAD represents ~5% of all cases and the age at onset varies from 30 
years to 65 years (Reitz and Mayeux 2014).  
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2.1. Genetics of Alzheimer’s Disease 
AD can be divided into familial cases that follow Mendelian inheritance (Familial 
AD) and sporadic cases in which there is no familial link. There are three principal genes 
that present rare and highly penetrant mutations which lead to FAD: amyloid precursor 
protein (APP), presenilin 1 (PS1) and presenilin 2 (PS2). These mutations culminate in 
alterations in Amyloid β Precursor Protein (APP) breakdown and Aβ peptide generation 
(Reitz and Mayeux 2014). Although the sporadic form is usually related with the 
combination of genetic and environmental factors, several studies have pointed out 
several genetic risk factors such as the epsilon4 allele in apolipoprotein E (Piaceri, 
Nacmias et al. 2013, Reitz and Mayeux 2014). 
2.2. Pathology of Alzheimer’s Disease 
AD is a devastating incurable neurodegenerative disorder characterized by the 
occurrence of extraneuronal amyloid plaques (figure 4A), consisting of aggregates of Aβ 
peptide and intraneuronal neurofibrillary tangles (NFT) (figure 4B) composed of 
aggregates of abnormally hyperphosphorylated tau protein particularly in the 
hippocampus and cortex, the regions responsible for cognition and memory  (Castellani, 
Rolston et al. 2010, Li and Buxbaum 2011). The senile plaques can be distinguished into 
multiple subtypes, being the neuritic plaques the most pathogenically relevant and the 
ones used to diagnose AD at autopsy (Castellani, Rolston et al. 2010). NFT are mostly 
characterized in terms of localization since they can be related to lesions such as neuropil 
threads (thread like accumulations within neuropil of gray matter and white matter) and 
dystrophic neuritis (terminal neuritic swellings) that arise within neuritic plaques 
(Castellani, Rolston et al. 2010). Other hallmarks of AD are neuronal and dendritic loss, 
synaptic loss, granulovacuolar degeneration, Hirano bodies and cerebrovascular amyloid 
(Castellani, Rolston et al. 2010).  
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Figure 4 - Two pathological features of AD: senile plaques (A) and neurofibrillary tangles (B) (both seen 
with Bielshowsky silver staining). Adapted from: (Castellani, Rolston et al. 2010) 
2.3. The Amyloid β Precursor Protein processing and Aβ generation  
2.3.1. The amyloidogenic pathway 
Senile plaques are formed by Aβ aggregates that result from the cleavage of a 
larger precursor protein named APP. APP is a transmembrane protein which is abundantly 
expressed in the CNS, but is also present in peripheral tissues such as epithelium and 
blood cells (Paula 2009). The cleavage and processing of APP involves two distinct 
pathways: the non-amyloidogenic and the amyloidogenic routes. In the first, APP is 
cleaved by the α-secretase, producing a large amino (N)-terminal ectodomain (sAPPα) 
that is secreted into the extracellular environment. This cleavage occurs within the Aβ 
region, thus preventing its formation. The produced fragment (named C83) is engaged in 
the membrane and is then cleaved by γ-secretase, producing a short fragment termed p3. 
In the amyloidogenic pathway, the first proteolytic step occurs through the action of β-
secretase, releasing sAPPβ into the extracellular medium and keeping a fragment named 
C99 within the membrane. This fragment is then cleaved by the γ-secretase, resulting in 
the formation of an intact Aβ peptide (figure 5) which is released into the extracellular 
space (LaFerla, Green et al. 2007).  
Mutations in APP, PS1 and PS2 (two γ-secretases), as mentioned above, affect 
the metabolism and stability of Aβ (LaFerla, Green et al. 2007). The most common APP 
mutation is the Swedish mutation (APPswe), in which a double amino acid change 
(K670N, M671L) results in increased APP cleavage by β-secretase (Haass, Lemere et al. 
1995). Also, mutations in the presenilin, such as the PS1A246E mutation, lead to 
increased levels of Aβ42 (Aβ peptide composed of 42 aminoacids) (Jankowsky, Fadale et 
al. 2004).  
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Figure 5 – Schematic diagram of APP processing and Aβ formation. While in the non-amyloidogenic 
pathway, APP is cleaved by α-secretase forming sAPPα (nontoxic), in the amyloidogenic pathway, the 
subsequent proteolysis of APP by β- and γ-secretases gives rise to Aβ peptide that accumulates in the 
extracellular environment.  Adapted from (LaFerla, Green et al. 2007). 
2.3.2. Aβ peptide and its assembly states 
As stated before, extracellular Aβ fibrils are the major constituent of senile plaques. 
Amyloid is characteristically congophilic, thioflavin S positive and highly insoluble in most 
solvents (Castellani, Rolston et al. 2010). The protein was shown to be composed of 42-
43 amino acids derived from the larger APP (Glenner and Wong 1984). This 4kDa peptide 
has a β-pleated sheet configuration and its length can vary at the c-terminus, depending 
on where the γ-secretase cleaves APP (Perl 2010). In the brain, the most abundant Aβ 
forms are Aβ40 and Aβ42, being the levels of Aβ40 higher than Aβ42 ones (LaFerla, Green et 
al. 2007). The latter is more hydrophobic and more prone to fibril formation, being the 
major isoform in senile plaques (Jarrett, Berger et al. 1993). Aβ can exist in different 
assembly states: it is released as monomers which gradually aggregate into dimers, 
trimmers, oligomers, protofibrils and fibrils to finally deposit and form amyloid plaques 
(Paula 2009) (figure 6).  
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Figure 6 – Schematic diagram of Aβ assembly states. Aβ exists in several assembly states – monomers, 
dimers, oligomers, protofibrils, fibrils and plaques.  
2.4. Aβ oligomers: the main toxic form 
Soluble Aβ oligomers are defined as Aβ assemblies which stay in solution after 
high-speed centrifugation, however these forms can bind to other macromolecules or to 
cell membranes, becoming insoluble. There are several types of Aβ oligomers that can 
derive from natural and synthetic Aβ (Table 1) (Haass and Selkoe 2007). Dimers and 
trimmers have been indicated as the building blocks of larger oligomers and insoluble 
amyloid fibrils since they were found in soluble fractions of human brain and amyloid 
plaque extracts (Walsh, Tseng et al. 2000). These low molecular weight oligomers are 
highly toxic in vitro, being dimers threefold more toxic than monomers and tetramers 13-
fold more toxic (Ono, Condron et al. 2009). Also, different molecular-weight synthetic Aβ 
oligomers have been developed and their toxic nature has been confirmed. For instance, 
small Aβ globular oligomers (5 nm in diameter) known as Aβ-derived diffusible ligands 
strongly bound to the dendritic arbors of cultured neurons, leading to neuron death and 
blocking long-term potentiation (a typical model for synaptic plasticity and memory loss) 
(Lambert, Barlow et al. 1998).  
Aβ oligomers have been pointed out as key players in AD pathology. Several 
studies suggest that soluble Aβ, including soluble oligomers, are the species linked to the 
presence and degree of cognitive deficits rather than the amyloid plaques (McLean, 
Cherny et al. 1999, Wang, Dickson et al. 1999, Naslund, Haroutunian et al. 2000). The 
larger contact between the neuronal membranes and a multitude of small oligomers rather 
than a low contact with larger fibrillar plaques (due to a small Aβ surface area) might 
explain why soluble assembly forms are much likely able to induce neuronal and/or 
synaptic dysfunction than plaques (Haass and Selkoe 2007). 
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Table 1 – Oligomeric assemblies of Aβ. Adapted from (Haass and Selkoe 2007) 
OLIGOMERIC ASSEMBLY CHARACTERISTICS 
Protofibril  
Intermediates of synthetic Aβ fibrillization; up to 150 nm in 
length and ~5 nm in width; β-sheet structure: bind Congo red 
and Thioflavin T 
Annular assemblies 
Doughnut-like structures of synthetic Aβ; outer diameter of 
~8–12 nm; inner diameter of ~2.0–2.5 nm 
Aβ-derived diffusible ligands 
Synthetic Aβ oligomers smaller than annuli; might affect 
neural signal transduction pathways 
Aβ*56 
Apparent dodecamer of endogenous brain Aβ; detected in 
the brains of an APP transgenic mouse line and might 
correlate with memory loss 
Secreted soluble Aβ dimers 
and trimers 
Produced by cultured cells; resistant to SDS; alter synaptic 
structure and function 
2.5. Models of Alzheimer’s Disease 
The development of transgenic mouse models of AD has opened new insights in 
the development of the pathology and in the discovery of new therapeutic targets. Several 
AD mice models have been described so far and most of them carry mutations in APP, 
PS1 or PS2, displaying features characteristic of AD. Since TTR has been suggested as 
a neuroprotector in this pathology, AD mouse models transgenic for TTR have been 
created. An AD mouse model that carried the APP Swedish mutation (APP23 mice) 
showed co-localization of TTR and Aβ in the amyloid deposits (Buxbaum, Ye et al. 2008). 
The APP23/hTTR+ mice, that resulted from the crossing of a mouse strain that 
overexpresses human TTR WT with the APP23 mice, showed normalized cognitive 
function and spatial learning besides presenting a reduction in the amounts of deposited 
Aβ (Buxbaum, Ye et al. 2008). In this study, authors also showed that the existence of two 
copies of ttr gene has a great impact in the development of the disease than having only 
one copy (Buxbaum, Ye et al. 2008). However, other studies have proven the opposite. 
TgCRND8/TTR+/- mice presented reduced Aβ plaque burden in the hippocampus when 
compared with TgCRND8/TTR+/+ mice (Doggui, Brouillette et al. 2010). In studies using 
APPswe/PS1A246E transgenic mice (that presented accelerated Aβ deposition in the 
hippocampus and in the cortex) crossed with TTR null mice, females mice showed 
increased Aβ levels when comparing with their male counterparts and mice with only one 
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copy of ttr gene also exhibited higher Aβ levels, suggesting then a gender-dependent 
modulation of Aβ levels (Oliveira, Ribeiro et al. 2011).   
Although mice are the leading animal model in the neurodegeneration field, 
zebrafish has emerged as new valuable animal model for disease modelling, mechanistic 
studies and therapeutic testing due to its unequaled advantages: the ease to quickly and 
cheaply generate a large number of animals, their transparency during development and 
the large number of available techniques to modulate their genetics and phenotypes 
(Martin-Jimenez, Campanella et al. 2015). Notably, zebrafish possesses the orthologues 
of the genes known to be involved in AD, i.e., ps1, ps2 and app (Newman, Verdile et al. 
2011). Since these genes have not yet been fully studied, the development of an AD 
zebrafish model that presents the AD pathological characteristics and that relies on the 
mutation of such genes has not been achieved yet. Nevertheless, an AD zebrafish model 
was created, showing cognitive defects and increased tau phosphorylation after Aβ 
injection in the brain ventricle of 24 hours post-fertilization (hpf) zebrafish embryos (Nery, 
Eltz et al. 2014). A different approach in which zebrafish embryos are incubated in an Aβ-
containing medium was also developed. Using a zebrafish line that expresses GFP in the 
vessels, Aβ was demonstrated to induce vessel reduction, impairment of angiogenesis 
and an increase reactive oxygen species, phenotypes that are frequently found in AD (Lu, 
Liu et al. 2014). 
2.6.  Therapeutic approaches for Alzheimer’s Disease 
The current therapeutic approaches for AD are based on the modulation of the 
effects created by specific hallmarks such as hyperphosphorylation of tau and the low 
levels of acetylcholine. Drugs that target the components of the amyloidogenic pathway 
are also being developed (Kumar, Nisha et al. 2015). The treatments approved so far 
aren’t able to delay the progression of neurodegeneration, relaying only in the 
maintenance of the patient functional ability and with less symptoms (Rabins and Blacker 
2007). Cholinesterase inhibitors such as donepezil have been approved by the Food and 
Drug Administration for the treatment of the cognitive impairment found in AD. Other drugs 
such as non-steroidal anti-inflammatory drugs have also been proposed to have beneficial 
effect at this level. However these treatments showed mild side effects and low efficacy in 
clinical trials (Rabins and Blacker 2007). Therefore, the development of new therapies that 
target other neurodegenerative processes found in this disease might be of great interest. 
It is currently believed that, in particular in the sporadic cases of AD which 
represent the majority of the cases, elimination of Aβ is compromised rather than its 
increased production (as it seems to be the case of familial cases). Therefore, amyloid-
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degrading enzymes have been suggested as valuable tool to modulate AD pathology. 
Neprilysin (NEP), a peptidase present in the neuronal surface, has been implicated in the 
degradation of Aβ peptide both in vitro and in vivo (Nalivaeva, Beckett et al. 2012). The 
lentiviral delivery of NEP to the brain of AD mice lead to a diminished amyloid pathology 
in these mice (Marr, Rockenstein et al. 2003). Other reports also stated that the early 
neuronal overexpression of NEP is beneficial since it diminishes Aβ levels and delays 
plaque formation and AD pathology (Leissring, Farris et al. 2003). A recent study, in which 
recombinant soluble NEP was administrated to an AD mice model, through a guide 
cannula placed in the hippocampal region, showed that soluble NEP is able to reduce Aβ 
plaque burden and to improve the memory defects on these mice (Park, Lee et al. 2013). 
Nevertheless, the role of other enzymes has also been addressed in this context. The 
involvement of insulin-degrading enzyme (IDE), a zinc endopeptidase present in neuronal 
cells, in Aβ clearance has been the focus of extensive research (Nalivaeva, Beckett et al. 
2012).  
 
3. NEURONAL CYTOSKELETON REMODELING IN PROTEIN AGGREGATION 
DISEASES  
The neuronal cytoskeleton has been identified as an essential component in the 
neurodegenerative process caused by the accumulation of specific prone-to-aggregate 
proteins. The most studied neurodegenerative disease with a strong cytoskeleton 
dysfunction is AD, since tau, that is a microtubule-associated protein (MAP), accumulates 
and forms NFTs. Nevertheless, Aβ has been also related to the neuronal cytoskeletal 
defects found in AD. Other disorders have also been investigated, such as Parkinson’s 
Disease (PD) and FAP, however there still is a lack of information regarding the effect of 
the accumulation of the disease-related proteins in the neuronal cytoskeleton.  
3.1. The neuronal cytoskeleton 
The cytoskeleton of eukaryotic cells is the structure that helps cells maintaining 
their morphology and internal organization. There are three main types of cytoskeletal 
polymers that can be distinguished by their diameter, type of subunit and subunit 
arrangement: microtubules (MTs), actin filaments and intermediate filaments (IFs).  
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3.1.1. Structure and organization of microtubules, actin filaments and 
intermediate filaments 
MTs are long protein polymers composed by subunits formed by α and β tubulins. 
MTs consist of 13 linear protofilaments assembled around a hollow core (25nm in 
diameter), that forms a polar structure with two different ends: a fast-growing plus end and 
a slow-growing minus end. This polarity is crucial to determine the movement along MTs 
(Cooper 2013).  
Both α-tubulin and β-tubulin bind to GTP that regulates polymerization. Shortly 
after polymerization GTP is hydrolyzed and the affinity of tubulin for adjacent molecules 
weakens, favoring depolymerizating and resulting in the dynamic state. MTs also undergo 
treadmiling, a dynamic process in which the plus end of the filament grows in length while 
the other one shrinks, due to the addition of tubulin molecules bound to GTP lost from the 
minus end to the plus end of the same MT (Cooper 2013). MT dynamics is tightly regulated 
by post-translational modifications of tubulin such as detyrosination/tyrosination, 
acetylation and polyglutamylation, that not only state the dynamic state of MTs but also 
were suggested to regulate binding affinity to motor proteins (Janke and Bulinski 2011). 
The molecular motors were shown to bind with higher affinity to acetylated and 
polyglutamylated MTs which constitute the most stable pools (Janke and Bulinski 2011). 
Furthermore, microtubule-associated proteins (MAPs) have also an important role in MT 
stabilization (for example, MAP1, MAP2, tau and collapsing response mediator proteins 
(CRMPs)) and destabilization (such as spastin and katanin) (Janke and Bulinski 2011). 
Besides their role on MT dynamics, a group of MAPs namely MT plus end-tracking 
proteins (+TIPs) control the interaction between MT and cellular organelles (Akhmanova 
and Steinmetz 2008). 
Due to their dynamic nature and their interaction with all these intracellular players, 
MTs are a key cellular component in the determination of the polarity of neurons and form 
the trails for intracellular transport of a high variety of structures. Intracellular transport is 
crucial for neuronal morphogenesis, function and survival (Hirokawa, Niwa et al. 2010). 
The long distance transport of cargos along the axon is carried out by three essential 
molecular motor superfamilies: kinesin, dynein and myosin (Hirokawa and Noda 2008). 
Both kinesin and dynein use ATP to move along MTs in different directions: kinesins walk 
toward the plus end (anterograde transport) and dyneins walk toward the minus end 
(retrograde transport) (Hirokawa, Niwa et al. 2010). In the axon, two types of transport 
exist: fast transport of membranous organelles and slow transport of cytosolic proteins 
and cytoskeletal proteins. 
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The actin cystoskeleton is composed of actin monomers (globular (G) actin) that 
have tight binding sites that enable head-to-tail interactions with two other actin 
monomers, so actin monomers polymerize to form thin, flexible fibers of approximately 7 
nm in diameter actin filaments (filamentous (F) actin). These filaments are organized into 
higher-order structures, forming bundles or three-dimensional networks. Since all the actin 
monomers are oriented in the same direction, actin filaments have a distinct polarity and 
the plus and minus ends are distinguishable. The reversible addition of monomers 
happens in both ends, but the plus end elongates five to ten times faster than the minus 
end. Actin monomers bind ATP which leads to a faster polymerization and is hydrolyzed 
to ADP after assembly (Cooper 2013). This process is tightly regulated by elongation 
factors such as profilin and formins and by depolymerization factors such as cofilin. 
Together these features make actin the engine behind the generation of the force 
necessary to regulate the neuronal shape and cellular internal and external movements 
(Edwards, Zwolak et al. 2014). 
IFs differ from MTs and actin by their size and primary structure of their constitutive 
proteins, their non-polar architecture and their relative insolubility. Each IF protein is 
composed of a conserved α-helix central region, called rod domains, which is flanked by 
non-α-helical head (amino-terminal) and tail (carboxy-terminal) domains (Lepinoux-
Chambaud and Eyer 2013). The assembly of IF proteins consists in two anti-parallel 
dimmers, which form protofilaments. A filament is finally composed of eight protofilaments, 
resulting in a diameter of 10 nm. IFs are divided into six sequence homology groups (types 
I to VI) depending on the cellular type in which they are present. Type IV IFs (neuronal-
specific) are neurofilaments (NFs) and their related proteins (NF-L, NF-M, NF-H, nestin, 
synemin, syncoilin and α-internexin) (Szeverenyi, Cassidy et al. 2008). The regulation of 
these proteins is achieved through post-translational modifications, such as 
phosphorylation, glycosylation and transglutamination (Lepinoux-Chambaud and Eyer 
2013). The main role of NFs in neurons is the stabilization of the other components of the 
cytoskeleton. 
3.1.2. Cytoskeleton organization in neurons 
During neuronal development and regeneration, each neuron has an axon which 
will continue to growth till its final destination. Growth cones, which are the tips of each 
axon, play a fundamental role in the elongation of the axon. The cytoskeleton organization 
has a crucial impact on nervous system injury. The adult CNS and the PNS differ greatly 
in the regenerative capacity, responding differently in terms of cytoskeleton reorganization 
after injury. While PNS neurons form a growth cone which allows regeneration, adult CNS 
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neurons, which are not able to grow after injury, develop dystrophic end bulbs or retraction 
bulbs, a hallmark of degenerating axons (Bradke, Fawcett et al. 2012). 
The growth cone can be separated into three domains based on the cytoskeletal 
components distribution. The central domain (C-domain), where the axon shaft 
terminates, is composed by bundles of stable MTs that enter into the growth cone and 
polymerize with their plus end toward the leading edge, and by vesicles, organelles and 
other proteins that are being transported into this domain. The actin filaments, that exist 
as both filopodia (packed actin bundles) and lamellipodia (sheet-like actin meshwork), 
constitute the peripheral domain (P-domain) and shape the growth cone and direct its 
propagation. Both types of actin filaments have their depolymerizing ends directed to the 
basal region of the growth cone, forming the transition zone (T-zone). In this thin band 
between the central and the peripheral domains, MTs and actin filaments interact what is 
crucial for axon extension (figure 7) (Neukirchen and Bradke 2011). 
 
Figure 7 - The structure of the neuronal growth cone. The growth cone is composed of three different 
zones: the central zone (C), the peripheral zone (P) and the transitional zone (T), which have different 
cytoskeletal elements composition. Adapted from (Lowery and Van Vactor 2009) 
Patches of actin filaments are present on the initial portion of the axon – axon initial 
segment (AIS) – and along the more distal axon shaft and in the dendrites. The presence 
of these structures in the AIS has been proposed to capture axonal transport cargoes, 
limiting their entrance into the axon, while their presence in the distal part is related with 
the formation of axonal collateral branches (Arnold and Gallo 2014). Recently, a novel 
form of actin filament organization was found: actin rings where actin is disposed in 
isolated rings associated with adducin and separated by spectrin tetramers were 
demonstrated along the shaft of the axon. In the axon shaft, MTs are aligned in parallel 
bundles that then splay apart within the growth cone (Xu, Zhong et al. 2013). In the 
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dendrites, MTs have a mixed polarity with both plus and minus ends towards these 
structures, being mainly involved with synaptic activity. Actin, in other hand, governs 
morphological and functional synaptic plasticity (Shirao and Gonzalez-Billault 2013). NFs 
are mainly present in axons, being essential for radial growth, the maintenance of axon 
caliber and the transmission of electrical impulses along axons (Yuan, Rao et al. 2012). 
These proteins, as long as actin and tubulin, are synthethized within the cell body and 
travel long distances to reach their sites of action (figure 8). 
 
Figure 8 – Schematic depiction of the neuronal cytoskeleton of developing neuron. A - The dendritic 
spines present mixed orientated microtubules and patches of actin; B - Actin rings are one of the main actin-
based structures in the axon; C – Axonal transport occurs through the action of molecular motors such as 
kinesin and dynein that move along microtubules; D – The growth cone is composed by highly motile 
microtubules, actin meshwork and actin arcs.  
3.2. Cytoskeleton alterations in neurodegenerative diseases 
Neurodegenerative disorders are a wide group of chronic neurological disorders 
that, depending on its origin, can be characterized clinically by slow progressive loss of 
motor/sensory functions and/or decreased perceptual function which might be associated 
with cognitive and behavioural deficits (Pal, Alves et al. 2014).  
In several neurodegenerative disorders, such as AD and Parkinson’s Disease 
(PD), affecting the CNS and FAP, which mainly affects the PNS, the presence of 
21 
 
aggregated forms of a given protein are a hallmark. Protein aggregation can be caused 
by a mutation in a disease-associated protein, by a genetic alteration that augments the 
amounts of a normal protein or by environmental stress or aging (Ross 2005). Protein-
aggregated structures can also be due to the inexistence of a defined tertiary structure or 
can also result from the partial unfolding of a proteins which usually has a well-defined 
tertiary and/or quaternary structure (Johnson, Connelly et al. 2012). In some diseases, 
large intracellular or extracellular deposits of aggregated protein are often formed (Ross 
2005). Many reports have been published showing the high toxicity of these structures 
that lead to neurodegeneration. Some of the potential causes of neurodegeneration 
investigated include: excitotoxicity, astroglia and/or microglia dysfunction, oxidative stress 
and mitochondrial dysfunction, endoplasmic reticulum stress, defects in axonal transport 
and RNA-processing and deregulation of metabolic and degradation pathways. 
Additionally, several studies showed that major axonal and cytoskeletal alterations are 
seen in diverse models of neurodegenerative diseases (Vickers, King et al. 2009). 
3.2.1. Alzheimer’s Disease 
AD is characterized by abnormal decline in cognition, which is associated with 
cytoskeletal changes in neurons and subsequent neurodegeneration (Suchowerska and 
Fath 2014). In AD patients, accumulation of cytoskeletal proteins is a common 
phenomenon. Hirano bodies, eosinophilic inclusions that are frequently observed in 
postmortem AD brains, were discovered to be composed by bundles of F-actin (Galloway, 
Perry et al. 1987). Furthermore, senile plaques within the brains of sufferers of AD are 
typically surrounded by dystrophic neurites (Tanzi, St George-Hyslop et al. 1989). Further 
studies using human AD tissue presented NFs accumulation in ring-like whorls or bulbous 
conformations (Vickers, King et al. 2009).  
Aβ aggregation is acutely toxic to neurons. Concerning cytoskeletal alterations, in 
vitro stimulation of the Ras-related C3 botulinum toxin substrate 1/ Cell division control 
protein 42 homolog  (Rac1/Cdc42) pathway (proteins of the Rho GTPase family, the major 
regulators of actin dynamics) with fibrillar Aβ1-42 increased actin polymerization, as shown 
by increased lamellipodia and filopodia formation in rat hippocampal neurons (Mendoza-
Naranjo, Gonzalez-Billault et al. 2007). Aβ aggregates were suggested to be sufficient to 
induce the formation of neuritic abnormalities in rat hippocampal neurons (Pike, 
Cummings et al. 1992) and, more recently, it was demonstrated that in SH-SY5Y cells and 
in a mouse model of AD, Aβ aggregates lead to reduction in the length of neurites by 
promoting CRMP-2 phosphorylation via Rac1 (Petratos, Li et al. 2008). Moreover, studies 
conducted with hippocampal brain tissue of AD patients showed increased Rac1/Cdc42 
expression when compared to age-matched controls (Zhu, Raina et al. 2000) what might 
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account for an excessive F-actin accumulation resulting in the formation of the observed 
Hirano bodies (Henriques, Oliveira et al. 2014). Cofilin-actin rods are intracellular 
inclusions primarily formed in the axons and dendrites of neurons due to the 
hyperactivitation by dephosphorylation of cofilin and that block transport within neurites 
(Bamburg and Bloom 2009).The existence of cofilin-actin rods in AD was verified both in 
vitro using neurons that were exposed to Aβ oligomers (Maloney, Minamide et al. 2005) 
and in vivo using human AD brains (Minamide, Striegl et al. 2000).  
 Nevertheless, the axonal transport defects are also due to alterations in the MT 
cytoskeleton and the deregulation of specific signaling pathways. Regarding the first, it 
was demonstrated that Aβ impacts on MT cytoskeleton. Deacetylated tubulin is related to 
a dynamic form of tubulin that blocks binding of motor proteins, thus axonal transport 
(Reed, Cai et al. 2006). Aβ decreases α-tubulin acetylation (Henriques, Vieira et al. 2010) 
and toxic concentrations of oligomeric Aβ1-42 were shown to promote MT stability 
independently of tau in primary neurons, being this effect mediated by RhoA pathway 
(Pianu, Lefort et al. 2014). Furthermore, the levels of histone deacetylase 6 (HDAC6), 
which is able to deacetylate α-tubulin, are increased in AD patients brains (Ding, Dolan et 
al. 2008). Additionally, Aβ oligomers were also shown to induce tau (that is usually in the 
axonal compartment) missorting to dendrites and a drastic reduction in the number of MTs 
(Zempel, Thies et al. 2010). Regarding the deregulation of signaling pathways, 
hippocampal neurons treated with Aβ oligomers exhibited vesicle and mitochondria 
transport defects via a mechanism that involves N-methyl-D-aspartate receptors 
(NMDARs) and glycogen synthase kinase 3-β (GSK3-β) (Decker, Lo et al. 2010). The 
transport of vesicles containing brain-derived neurotrophic factor after treatment with Aβ 
oligomers was also assessed and an impairment of the fast axonal transport related 
independently of tau was observed (Ramser, Gan et al. 2013). 
3.2.2. Parkinson’s Disease 
Parkinson’s Disease (PD) is a progressive neurodegenerative disorder of the CNS. 
PD commom symptoms include resting tremor, rigidity, gait impairment, bradykinesia and 
postural instability. The histopathological hallmarks in PD are the degeneration of 
dopaminergic neurons in the substantia nigra along with Lewy bodies (LB) - intracellular 
protein accumulations (Suchowerska and Fath 2014) being these structures mainly 
composed by α-synuclein, tubulin, MAPs and NFs (Galloway, Mulvihill et al. 1992).  
α-synuclein is a member of the synuclein family of proteins that has 140 amino 
acids and has no defined structure. When bound to negatively charged lipids, it acquires 
an α-helical structure, while, in longer incubation times, it gains a β-sheet-rich structure 
(Stefanis 2012). This protein is abundantly expressed in the nervous system and localizes 
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preferentially in the presynaptic terminals of neurons (George 2002). There are two well-
studied disease related-mutations of α-synuclein: A30P and A53T (Polymeropoulos, 
Lavedan et al. 1997, Kruger, Kuhn et al. 1998).  As other β-sheet-rich proteins, α-synuclein 
has a high propensity for aggregation. Indeed, WT as well as disease-related mutants 
form amyloid-like fibrils in long incubations, structures known for being the basis of the 
mature LB and lewy neurites. The α-synuclein aggregation cascade is similar to other 
known aggregation cascades: the natively unfolded protein initially forms soluble 
oligomers that assemble in protofibrils that eventually form fibrils (Stefanis 2012).   
Several reports have established the importance of the neuronal cytoskeleton in 
PD. Although the precise mechanisms by which α-synuclein act were not yet discovered, 
it is known that it has an important role on neuronal plasticity and synaptic regulation 
(Cheng, Vivacqua et al. 2011). Most studies have addressed the effect of α-synuclein on 
MTs and axonal transport. α-synuclein and tubulin were shown to interact with each other 
in vitro (Zhou, Huang et al. 2010), however conflicting effects on tubulin polymerization 
have been found (Alim, Ma et al. 2004, Zhou, Huang et al. 2010). Furthermore, MT 
instability has been proposed as an early event in the degeneration of dopaminergic 
neurons in a PD mice model (Cartelli, Casagrande et al. 2013).  
Axonal transport defects were also identified as one of the mechanisms behind α-
synuclein pathogenesis (Hunn, Cragg et al. 2015) and since dopaminergic neurons have 
long axons, cargo trafficking is vital for their life-maintaining processes. Cortical neurons 
overexpressing α-synuclein mutants (A30P and A53T) exhibited reduced axonal transport 
and transfection of these cells with A30P resulted in the accumulation of the protein 
proximal to the cell body, a process that might contribute to LB formation and neuritic 
defects (Saha, Hill et al. 2004).  
Efforts have been made to unravel the role of α-synuclein in the actin cytoskeleton 
in PD. Zhou et al demonstrated that α-synuclein interacts with the actin cytoskeleton 
components such as actin, cofilin and F-actin capping proteins (Zhou, Gu et al. 2004). 
Furthermore, the A30T mutant was shown to alter the actin cytoskeletal structure and 
dynamics in primary hippocampal neurons (Sousa, Bellani et al. 2009). Since, in this 
report, the aggregation status of this mutant was not assessed, further studies should 
verify if the aggregation status of α-synuclein impact on the actin cytoskeleton remodeling. 
3.2.3. Familial Amyloid Polyneuropathy 
TTR is a highly amyloidogenic protein that is related to FAP. In this autosomal 
dominant disease, TTR deposits preferentially in the PNS and forms fibril aggregates 
leading to nerve lesions. FAP typically causes a nerve length-dependent sensory-motor 
polyneuropathy and autonomic dysfunction (Plante-Bordeneuve and Said 2011, Saraiva, 
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Magalhaes et al. 2012). The systemic extracellular deposition of mutated TTR aggregates 
and amyloid fibrils is present in the connective tissue, with the exception of brain, liver and 
parenchyma, and has a major impact in the PNS. TTR has access to the nerve through 
the blood and CSF. In the peripheral branch, the fibrils are diffusely distributed, involving 
nerve trunks, plexuses and sensory and autonomic ganglia. Consequently, axonal 
degeneration becomes a feature of this disease, beginning in unmyelinated and 
myelinated fibers of low diameter and ending up in neuronal loss of ganglionic sites 
(Plante-Bordeneuve and Said 2011). 
The involvement of the neuronal cytoskeleton in this disorder is still under 
investigation. Unpublished in vitro data from our group revealed that mouse WT DRG 
neurons incubated with TTR oligomers show a marked reduction of the growth cone area, 
with disruption of the typical morphology of the growth cone presenting dystrophic MTs 
and lacking the lamellipodial actin structures (figure 9). Furthermore, using Drosophila 
Melanogaster in which TTR V30M is expressed in the photoreceptors cells resulting in 
roughening of the eye, our group has also verified a decreased axonal projection of 
photoreceptor neurons, that presented more compact growth cones lacking the spread 
distribution of filopodia and lamellipodia actin structures. Our group also performed a 
genetic screening in which TTR V30M flies were crossed with flies for the knockdown or 
overexpression of candidate genes that are related to the neuronal cytoskeleton. It was 
verified that overexpression of the major regulator of actin dynamics Rac1 reverted the 
TTR-induced rough eye phenotype, reinforcing the important role of the actin cytoskeleton 
and the associated signaling pathways in neurodegenerative process in FAP.  
 
Figure 9 - TTR oligomers induce alterations in the growth cone morphology of DRG neurons. (A) control  
DRG neurons present a typical growth cone morphology with lamellipodia and filopodia (red) and splayed 
microtubules (green). (B) WT DRG neurons incubated with TTR oligomers show an altered growth cone 
morphology being dystrophic and lackig lamellipodial actin structures. 
In the diseases described above, the neuronal dysfunction was suggested to occur 
as a result of the action of the noxious oligomers instead of the fibrils themselves. It has 
been proposed that oligomers composed by Aβ, α-synuclein and other prone-to-aggregate 
proteins share a common structure regardless of the differences present in their amino 
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acid side chains (Kayed, Head et al. 2003). This discovery might imply that a common 
pathogenic mechanism is behind the neurodegenerative process associated with protein 
misfolding and aggregation and this mechanism might be associated with the hydrophobic 
interaction of the oligomeric species with different cellular targets, such as the neuronal 
cytoskeleton (Agorogiannis, Agorogiannis et al. 2004). 
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OBJECTIVES 
Protein aggregation is a hallmark of several neurodegenerative disorders such as 
AD, PD and FAP. Aβ accumulation is considered the major pathological change in AD 
progression constituting a therapeutic target involving the use Aβ degrading enzymes. In 
this respect, TTR is a metalloprotease that was shown to cleave both soluble and 
aggregated forms of Aβ in vitro. Nevertheless, the relevance of TTR proteolysis in AD was 
not previously addressed and constituted the first main goal of this thesis (Chapter 2). For 
that we established the following objectives: 
i) Dissect the effect of TTR proteolytic activity on Aβ clearance and Aβ-
mediated neurotoxicity using both cell lines and primary neuronal cultures;  
ii) Investigate the role of TTR proteolytic activity in vivo using mice and 
zebrafish as AD models. 
The second aim of this thesis was to analyze the effect of different prone-to-
aggregate proteins, related with AD, PD and FAP, in the neuronal cytoskeleton (Chapter 
3), since common pathological mechanisms might be involved in the neurotoxicity induced 
by these proteins. In order to accomplish that, the following objectives were defined: 
i) Analyze the effect of Aβ oligomers in the growth cone morphology of 
hippocampal neurons and verify if TTR WT is able to rescue the resulting 
phenotype; 
ii) Dissect the effect of the different aggregation states of α-synuclein in the 
growth cone morphology of hippocampal neurons; 
iii) Study the effect of TTR WT and TTR mutants (V30M and L55P) in the 
growth cone morphology of hippocampal neurons; 
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CHAPTER 2 
TTR NEUROPROTECTIVE EFFECT IN AD DEPENDS 
ON TTR PROTEOLYTIC ACTIVITY 
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THEORETICAL BACKGROUND 
Alzheimer’s Disease (AD) is a neurodegenerative disorder clinically characterized 
by the progressive memory deficits and cognitive decline of the elderly. One of the 
hallmarks of AD is the extraneuronal accumulation of amyloid-β (Aβ) oligomers that results 
in the formation of amyloid plaques inducing neuronal dysfunction and cell death 
(Castellani, Rolston et al. 2010). Aβ is produced by the subsequent cleavage of the 
amyloid precursor protein (APP) by β- and γ-secretases (LaFerla, Green et al. 2007). Its 
levels are regulated by a balance between de novo synthesis of Aβ, aggregation and 
degradation. The dysfunction of these mechanisms occurs with aging and disease as AD. 
Transthyretin (TTR), a protein with metalloprotease activity, was suggested as having a 
neuroprotective role in AD as the protein was shown to be able to sequester Aβ, preventing 
amyloid formation and toxicity in vitro (Schwarzman, Gregori et al. 1994). Further studies 
verified that TTR protective capacity was related to its binding to toxic Aβ intermediates in 
both intracellular and extracellular environment in a chaperone-like manner (Buxbaum, Ye 
et al. 2008). Additionally, TTR was shown to be able to cleave Aβ in vitro in multiple 
positions, producing peptides with lower amyloidogenic potential (Costa, Ferreira-da-Silva 
et al. 2008). Unpublished data from our group in collaboration with the MIND group (IBMC) 
suggested that TTR proteolytic activity is required for the inhibition of Aβ fibril formation 
(figure 10) and for the disruption of Aβ fibrils (figure 11). This was shown by co-incubating 
either with TTR WT or a proteolytic inactive form (TTR H90A) with soluble or fibrillar Aβ. 
These results suggested that TTR proteolysis might underlie the neuroprotective effect of 
the protein, although this hypothesis was lacking support from in vivo data. In this work, 
we aimed at further dissecting the role of TTR proteolytic activity in AD both in cell based 
systems, using cell lines and primary neuronal cultures, and in vivo using mice and 
zebrafish, as AD models. 
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Figure 10 – TTR proteolytic activity impacts on Aβ fibrillization. Aβ peptide (soluble at t = 0) was incubated 
with or without TTR (either TTR WT or TTR H90A) and analyzed by TEM at days 1 and 6. The incubation of 
TTR WT with soluble Aβ showed an inhibition of Aβ fibrilization in vitro, an effect that was not seen with the 
incubation with TTR H90A. 
 
 
Figure 11 – TTR proteolytic activity is required for the disruption of Aβ fibrils. Aβ fibrils were grown for 
10 days at 37 ºC (t=0); then either TTR WT or TTR H90A was added and further incubated at 37ºC and 
analyzed at different time points (1, 2 and 4 days) by TEM. The incubation of TTR WT with Aβ fibrils led to the 
generation of Aβ fragments of decreased size, while the incubation with TTR H90A did not have this effect.  
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 MATERIALS AND METHODS 
TTR production, purification and labeling 
Recombinant TTR WT and TTR H90A (TTR proteolytically inactive) were produced 
in BL-21 pLys Escherichia coli cells transformed with pET plasmids carrying TTR cDNA 
as previously described (Furuya, Nakazato et al. 1989). The protein was isolated and 
purified as previously described (Liz, Faro et al. 2004). Briefly, after osmotic shock of 
bacteria, protein extracts were run on a diethylaminoethyl (DEAE)-cellulose (Whatman) 
ion exchange chromatography, dialyzed, lyophilised and isolated in native preparative 
Prosieve agarose (Lonza) gel electrophoresis. After electrophoresis, the TTR band was 
excised and eluted in 38 mM glycine, 5 mM Tris pH 8,3 overnight (O/N) at 4ºC. The protein 
was then detoxified using a high capacity endotoxin removal resin (Thermo Scientific) and 
quantified by Lowry’s method using BioRad DC protein kit.  
TTR WT was labeled with Alexa 488 using Alexa Fluor 488 Protein Labeling Kit 
(Life Technologies). Briefly, TTR was diluted 1:10 in 1M bicarbonate pH 8,3 and stirred for 
1h at RT in the reactive dye vial. Labelled TTR (referred as TTR-488) was then purified 
through size exclusion purification BioGel P-30 Fine resin (Bio-Rad). 
TTR proteolysis assay 
The enzymatic activity was measured as previously described. TTR (5 µM) was 
added to Abz-VHHQKL-EDDnp (5µM; Genscript) in 50 mM Tris pH 7,5. The fluorescence 
at λem = 420 nm and λex = 320 nm was measured in a fmax plate reader (Molecular Devices) 
at 37ºC for 30 min. 
Production of Aβ oligomers 
Aβ peptide (Genscript) was dissolved in hexafluoroisopropanol (HFIP, Sigma) and 
incubated O/N at room temperature (RT). The HFIP was removed under a stream of 
nitrogen and the residue was then dissolved in dimethyl sulfoxide (DMSO, Sigma) at 2 
mM. For oligomers formation, Aβ was diluted at a final concentration of 10 µM in F12 
medium (Lonza) and incubated for 5 days at 4ºC, pH 7. To assess the assembly state of 
the Aβ, transmission electron microscopy using negative staining was performed at 
50000x magnification. 
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N2A cell culture 
Neuro-2 A neuroblastoma cells stably expressing human APP carrying a double 
mutation at codons 670 and 671 (N2A-APPswe) were kindly provided by Dr. Huaxi Xu 
(Sanford-Burnham Medical Research Institute, California, USA). 
 N2A-APPswe cells (at a density of 50000 per well) were plated on a 24 well plate 
and were maintained in 1:1 Dulbecco's Modified Eagle Medium/F12 (DMEM/F12; Sigma) 
/ Opti-Minimum Essential Medium (Opti-MEM; Gibco) mixture supplemented with 5% FBS 
and 0,4% geneticine (Gibco). When 90% confluence was reached, the medium was 
substituted by a starvation medium constituted by 1:1 Opti-MEM/DMEM medium enriched 
with 0,4% geneticine (Gibco) containing 5 µM of either TTR WT or TTR H90A. Cells were 
maintained for 24h and the medium was collected and kept at -80ºC till use. 
Hippocampal neurons culture 
Hippocampi were isolated from WT embryos (NMRI mice) at E17.5 and maintained 
in Hank's Balanced Salt Solution (HBSS, Sigma). Cells were digested with 0,06% trypsin 
(Sigma) in HBSS  for 15 min at 37ºC, followed by addition of HBSS with 10% fetal bovine 
serum (FBS, Invitrogen) to stop digestion. After the washing steps, hippocampi were 
ressuspended in Neurobasal medium (Gibco) supplemented with 1% Pen/Strep (P/S, 
Invitrogen), B27 (Gibco) and L-Glutamine (Gibco) and were dissociated with two different 
diameter tips (P200 and P1000). The cell suspension was filtered and plated at a density 
of 150000 cells per well in coverslips previously coated with 20 µg/ml poly-L-lysine 
(Sigma). 
Caspase 3 fluorimetric assay 
After 5 days in vitro (DIV), cells were treated with 10 µM Aβ oligomers plus 5 µM 
of either TTR WT or TTR H90A and maintained for 24h at 37ºC. Cells were then lysed 
with lysis buffer (25 mM HEPES pH 7.4, with 2,5 mM CHAPS and 2,5 mM DTT), 
centrifuged at 13000 rpm for 20 min at 4ºC and supernatants were kept at -80ºC till use. 
To assess apoptotic cell death, caspase 3 assay was performed using Caspase 3 
Fluorimetric Assay Kit (Sigma). This assay is based on the hydrolysis of the peptide 
substrate acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC) by 
caspase 3, resulting in the release of the fluorescent 7-amino-4-methylcoumarin moiety. 
Samples were incubated with Ac-DEVD-AMC previously diluted in Assay Buffer for 90 min 
and subsequently the fluorescence at λem = 460 nm and λex = 360 nm was measured in a 
plate reader (Biotek Synergy MX).  
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In vivo experiments 
Transgenic mouse model and intracerebral administration 
APPswe/PS1A246E/TTR+/+ (referred as AD/TTR+/+) and APPswe/PS1A246E/TTR-
/- (referred as AD/TTR -/-) transgenic mice, kindly provided by Isabel Cardoso (MIND group, 
IBMC), were used to perform TTR intracerebral injections.  These mice were generated 
by crossing APPswe/PS1A246E transgenic mice with TTR null mice (TTR-/-), generating 
APPswe/PS1A246E/TTR+/+, APPswe/PS1A246E/TTR+/- and APPswe/PS1A246E/TTR-/- 
mice (Oliveira, Ribeiro et al. 2011). Animals were maintained in a controlled environment 
(12h light/dark cycle; temperature, 22 ± 2ºC; humidity, 45-65%) with food and water ad 
libitum. All the procedures followed National and European Union Guidelines for the care 
and use of laboratory animals. 
In the pilot experiments, 15 and 16 months old female AD/TTR-/- mice (n=2 for 
each condition) were anesthetized with a mixture of ketamine (75 mg/kg) and 
medetomidine (1 mg/kg) administrated by intraperitoneal injection. For continuous 
intracerebral administration of TTR, mini osmotic pumps (rate: 0.5 µl/hr; Alzet) were placed 
unilaterally in the right hippocampus (AP -2,3; ML -1,5; DV -1,7). Approximately 24h prior 
to implantation, the pumps were filled either with 63 µg of TTR WT diluted in 100 μl of 
Phosphate-buffered saline (PBS) (to achieve a delivery of approximately 9 μg per day) or 
only with PBS, and were kept in PBS at RT until the time of surgery. To assess the 
intracerebral localization of TTR, a female AD mouse was injected with TTR-488 diluted 
in PBS using the same conditions. 
In the following experiments, mini osmotic pumps were filled either with 63 µg of 
TTR WT or TTR H90A diluted in PBS. Female AD/TTR+/+ mice of 9 months of age were 
anesthetized and the pumps were placed as described above. As a control, two non-
injected female AD/TTR+/+ mice were used. 
Tissue processing  
  Pilot experiments 
Tissue processing was performed as previously described (Ribeiro, Oliveira et al. 
2014), with some modifications depending on the purpose.  
8 days post administration, the animals were anesthetized and the brain was 
removed. For the determination of Aβ levels in the test animals, the ipsilateral side of the 
brain was homogenized in lysis buffer (2 mM ethylenediamine tetraacetic acid (EDTA), 50 
mM Tris buffered saline (TBS) (pH 7.4),0.1% Triton X-100 with protease inhibitors cocktail) 
and centrifuged at 13000 rpm for 15 min at 4ºC. The supernatant was collected, aliquoted, 
and frozen at −80ºC for further analysis (detergent-soluble fraction of brain Aβ). To obtain 
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the formic acid soluble fraction of brain Aβ, the pellet was dissolved in 70% formic acid in 
distilled water and centrifuged as stated above. The supernatant was collected and 
neutralized with 1 M Tris (pH 11.0) (1:20 dilution), aliquoted, and frozen at −80◦C till use. 
In the contralateral side, immunohistochemistry was performed. The contralateral side of 
the brain, used for Aβ immunohistochemistry, was fixed for 24h at 4ºC in 10% neutral 
buffered formalin and then transferred to a 30% sucrose solution for cryoprotection before 
cryostat sectioning. 
In order to verify the localization of administrated TTR, animals injected using the 
same methodology with TTR-488 were anesthetized and then perfused with 4% 
paraformaldehyde (PFA). The brain was removed and postfixed with 4% PFA for 2-4h at 
4ºC and then incubated with 30% sucrose solution at 4ºC until equilibrated. The brains 
were frozen using liquid nitrogen and then kept at -20ºC till use. Sequential 20 µm coronal 
cryosections were taken on a cryostat and mounted with Vectashield with DAPI. Images 
were captured at 10x magnification in a fluorescence microscope (Leica DMI 6000B).  
 
Treated animals 
8 days post-TTR administration, the animals were anesthetized and then 
sacrificed. The hippocampus and the superior portion of the cortex (figure 12) of each side 
of the brain was dissected and treated independently. The detergent soluble and formic 
acid soluble Aβ fractions of both the hippocampus and cortex were homogenized as 
described above.  
 
Figure 12 – Representative image of the superior region of the cortex used for Aβ levels determination 
(green). 
 
Immunohistochemistry 
Aβ immunohistochemistry was performed as previously described (Ribeiro, 
Oliveira et al. 2014). Briefly, free floating 30 µm-thick half-brain cryosections were 
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incubated with 70% formic acid for 15 min at RT in slow agitation. The endogenous 
peroxidase activity was blocked with 1% hydrogen peroxide for 20 min. Sections were 
then incubated with blocking buffer composed by 10% FBS and 0.5% Triton X-100 for 1h 
at RT, followed by incubation with biotinylated 6E10 primary antibody (1:750 in blocking 
buffer; Covance Research Products, Inc.) O/N at 4ºC in slow agitation. After the incubation 
with Vectastain® Elite ABC Reagent (Vector Laboratories), sections were developed with 
diaminobenzidine (DAB;Sigma) and mounted on slides coated with 0.1% gelatin. An 
Olympus BX50 light microscope was used in the analysis of the sections.  
Aβ42 Enzyme-Linked Immunosorbent Assay (ELISA)  
Aβ levels were evaluated by ELISA assay using Human Aβ42 chromogenic-based 
kit (Invitrogen). Firstly, Aβ42 standards were reconstituted with Standard Reconstitution 
buffer to 1 µg/ml. Cell supernatants from N2A-APPswe cells and brain samples from AD 
mice were then diluted in standard diluent buffer supplemented with 1 mM 
phenylmethylsulfonyl fluoride (PMSF; Sigma) to avoid proteolysis of Aβ peptides. All 
samples were incubated with the detection antibody solution for 3h at RT or O/N at 4ºC. 
After the washing steps, samples were incubated with an anti-rabbit IgG horseradish 
peroxidase (HRP) working solution for 30 min, which was replaced by the stabilized 
chromogen (30 min at RT and in the dark). Finally, stop solution was added and the 
absorbance at 450 nm was read using a plaque reader (Thermo Scientific). Total protein 
quantification was performed using Lowry’s method (DC Protein Assay Kit, BioRad). 
Zebrafish experiments 
Zebrafish models 
The transgenic zebrafish line, which expresses GFP in the endothelial cells 
(referred as Veins), and WT zebrafish were kindly provided by José Bessa (VDR group, 
IBMC). The transgenic line Veins is an unpublished reporter line that was generated by a 
random mobilized transposon, described by Bessa and colleagues, containing an 
enhancer trap cassette (Bessa, Luengo et al. 2014). 
Zebrafish embryos were generated by synchronized natural pair-wise mating of 
adult fish and were used at single cell stage, 12 somites (14 hpf) and 24 hpf (Table 2), 
depending on the experimental procedures as described below. Embryos were grown at 
28ºC in 0.003% 3-phenyl-thiourea diluted in E3 medium (PTU medium; used to inhibit 
pigmentation). Veins were generated by out-crossing female transgenic animals with WT 
males.  
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Table 2 – Zebrafish stages of development at 28,5ºC. 
PERIOD STAGES 
HOURS 
POST-FERTILIZATION 
REPRESENTATIVE IMAGE 
Blastula Single cell 0 
 
Segmentation 12 somites 14 
 
Pharyngula Prism 5 24 
 
Larval 
Protruding-
mouth 
72 
 
 
Cell and yolk injections 
Single cell stage WT embryos were microinjected in the yolk and in the cell with 
5nl of  5, 10, 25, 33, 80, 200 and 500 µM Aβ peptide diluted in injection solution (10% 
phenol red 0.01 µg/µl IgG and  in PBS). 10% and 25% DMSO diluted in PBS were used 
as control for the higher Aβ concentrations (200 and 500 µM, respectively). 10 µM TTR 
WT was also injected in the yolk of single cell stage WT embryos. Embryo viability was 
assessed after 24h.  
Western Blot 
To detect Aβ by Western Blot, two protocols were tested for the preparation of 
tissue extracts. In the first protocol, 24h post-injection, embryos were de-chorionated and 
their yolk disrupted by pipetting up and down in Ginsburg Fish Ringers solution (111 mM 
NaCl, 3,6 mM KCl, 2,7 mM CaCl2 and 1,9 mM NaHCO3), followed by slow agitation (1100 
rpm) for 5 min at RT and centrifugation (500 g) for 5 min at 4ºC. After removing the 
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supernatant, embryos were washed with ice-cold PBS and centrifuged at the same 
conditions. The pellet was then resuspended in sample loading buffer (SLB) (40 µl of SLB 
per 50 embryos) and kept at -20ºC till use. Samples were thawed and heated at 100ºC for 
5 min and centrifuged at 13000 rpm for 5 min.  
In the second protocol, the above procedure was performed with slight variations: 
i) the addition of 0,3 mM PMSF to the Ginsburg Fish Ringers solution and ii) the 
homogenization of the embryos with extraction buffer (10 mM Tris pH 7.4, 2% Triton X-
100, 1 mM PMSF and protease inhibitors cocktail in water; 1,5 µL per embryo). Then, the 
samples were frozen in liquid nitrogen, centrifuged at 13000 rpm for 20 min at 4ºC and the 
supernatants kept at -80ºC till use.  
Samples (corresponding to 25 and 30 embryos in the first and second protocols, 
respectively) were run in a 15% SDS-PAGE gel and then transferred to a nitrocellulose 
membrane (0.45 mm; GE HealthCare). The transference was performed in a wet system 
using Tris-Glicine buffer with 20% methanol at 25 V, O/N at 4oC with magnetic agitation. 
The membrane was washed with deionized water, followed by a wash with TBS and then 
with TBS-T (TBS with 0,05% Tween). Subsequently, the membrane was incubated with 
blocking solution (5% milk (Sigma) in TBS-Tween) for 1h at RT. The membrane was 
incubated with anti-Aβ (1:1000; Sigma) or anti-TTR primary antibodies (1:1000, DAKO) in 
5% milk for 1h at RT. The membrane was washed 3 x 10 min in TBS with 0,05% Tween 
and then incubated with HRP conjugated anti-mouse (1:3000, Santa Cruz Biotechnology) 
or anti-rabbit secondary antibodies (1:3000, Santa Cruz Biotechnology) diluted in 3% milk 
in TBS-T for 1h at RT. Immunodetection was performed by chemiluminescence using ECL 
reagent (Bio-Rad). 
Brain intraventricular TTR injection 
At 24hpf, WT embryos had their chorion manually removed. Embryos were 
anesthetized with tricaine (Sigma) and placed in an agar coated petri dish. Under the 
stereomicroscope, the embryos were injected in the ventricle using a micromanipulator 
attached to an injector pump with 5 nl of: i) TTR-488 (0,63 μg/μl); or ii) Aβ peptide at either 
200 µM or 500 µM. Images were captured after 24h in a fluorescence stereomicroscope 
at 4x magnification. 
Angiogenesis assay and Aβ peptide treatment 
The assay was performed according to a previous study (Lu, Liu et al. 2014). 5 µM 
Aβ peptide diluted in PTU medium was administrated to Veins embryos at the 
developmental stage of 12 somites until 72hpf. The solution was renewed every 24h. 
Control embryos were maintained in 0.25% dimethyl sulfoxide (DMSO) in PTU. 72hpf 
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treated larvae (Table 2) were anesthetized with tricaine (stock solution 4g/l) and observed 
at the fluorescent stereomicroscope at 9x magnification. The area of the subintestinal 
vessels that extend into the yolk region of 3 embryos per condition was examined using 
Fiji software.  
Acridine orange immunohistochemistry 
Embryos were dechorionated at 72hpf and placed in 5 µg/ml of the vital dye 
acridine orange (Molecular Probes) for 5 min. For visualization in the fluorescent 
stereomicroscope at 9x magnification, embryos were anesthetized with tricaine. 
Statistical Analysis 
Results are presented as means ± SEM or means ± SD. All analyses were 
calculated with Student’s t-test test by using GraphPad Prism Software: *p<0.05; **p<0.01; 
***p<0.001. 
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RESULTS 
TTR proteolytic activity is required for Aβ clearance in a cell based system 
In order to assess the proteolytic activity of the TTR forms used in the following 
experiments, the fluorogenic Abz-VHHQKL-EDDnp peptide was incubated either with TTR 
WT or TTR H90A. As seen in figure 13, while TTR WT is able to cleave Aβ, TTR H90A is 
not, demonstrating that TTR H90A, that will be used in the following experiments, is 
proteolytic inactive. 
 
Figure 13 – Assessment of TTR proteolytic cleavage of the fluorogenic peptide Abz-VHHQKL-EDDnp. 
TTR WT is able to cleave the fuorogenic peptide while TTR H90A is not. (Ctrl - Abz-VHHQKL-EDDnp peptide; 
TTR H90A - Abz-VHHQKL-EDDnp incubated with TTR H90A; TTR WT - Abz-VHHQKL-EDDnp peptide 
incubated with TTR WT) 
TTR was previously shown to be able to cleave Aβ in vitro (Costa, Ferreira-da-
Silva et al. 2008). To investigate if this effect was maintained in a cell-based system, N2A-
APPswe cells that carry the Swedish mutation of APP and secrete high levels of Aβ 
peptide were incubated with either TTR WT or TTR H90A. 
N2A-APPswe cells treated with TTR WT showed 2,4-fold reduction Aβ levels 
(figure 14). Addition of TTR H90A had no effect on Aβ levels when compared to control 
cells, showing that the decreased Aβ levels after treatment with TTR WT are related with 
proteolysis (figure 14). These results show that TTR proteolytic activity is maintained in a 
physiological environment and impacts on Aβ clearance. 
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Figure 14- Analysis of Aβ clearance induced by either TTR WT or TTR H90A using N2A-APPswe cells. 
The incubation of N2A-APPswe cells with TTR WT lead to decreased Aβ levels while the incubation with TTR 
H90A had no effect. Statistical analysis: Results showed as means ± SEM. Student’s t-test - *p < 0.05, **p < 
0.01, ***p < 0.001 
Aβ-induced death of hippocampal neurons is decreased by TTR proteolysis  
Hippocampal neurons have been widely used as a cellular model of Aβ-induced 
neurotoxicity, since these neurons are the most affected in AD (Hu, He et al. 2015). To 
evaluate the effect of TTR proteolytic activity on neuronal cell death induced by Aβ 
oligomers, mouse hippocampal neurons were incubated with 10 µM Aβ oligomers plus 
either TTR WT or TTR H90A.  
To assure that the production of Aβ oligomers was achieved, electronic microscopy 
analysis was performed and, in fact, the incubation of Aβ at the referred above conditions 
successfully produced Aβ oligomers (figure 15A). The cytotoxic effect was evaluated using 
caspase-3 assay. 
In hippocampal neurons, Aβ oligomers induced neurotoxicity as suggested by the 
increased levels of caspase-3 activity (figure 15B). TTR WT was able to decrease in 28% 
the toxic effect induced by Aβ oligomers. However the TTR-induced neuroprotective effect 
was not reproduced with the addition of TTR H90A (figure 15B). These results show that 
only proteolytically active TTR is able to reduce Aβ-induced cell death, suggesting that 
TTR proteolytic activity is required for its neuroprotective effect in AD. Although the two 
TTR forms increased caspase-3 activation when comparing with the control, the levels 
were still below the ones of Aβ oligomers. The induction of cell death might be justified by 
the partial aggregation ability retained by these variants (figure 15B).  
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Figure 15 - TTR neuroprotective effect on Aβ oligomers induced neurotoxicity is dependent on TTR 
proteolytic activity. (A) TEM analysis of Aβ oligomers. (B) Caspase-3 assay showed that TTR WT was able 
to decrease the neurotoxic effect caused by Aβ oligomers on hippocampal neurons while TTR H90A had no 
effect. Statistical analysis: Results showed as means ± SEM. Student’s t-test - *p < 0.05, **p < 0.01, ***p < 
0.001 
TTR intracerebral administration has no effect on Aβ levels of AD mice 
AD/TTR mice were intracerebraly administrated with TTR variants in order to test 
TTR proteolytic activity in vivo. In this animal model, Aβ deposition starts at 6 months of 
age and females present higher brain Aβ levels (Oliveira, Ribeiro et al. 2011). We started 
by confirming the brain localization of injected TTR-488. As represented in figure 16A, 
TTR was localized in the hippocampus only in the ipsilateral side. However, accumulation 
of TTR-488 close to the injection site was also verified (figure 16B). 
In the pilot tests, 15 and 16 months old AD/TTR-/- female mice were injected in the 
right hippocampus using an osmotic pump previously filled with either PBS or TTR WT. 
After 8 days, animals were sacrificed and both detergent soluble and formic acid soluble 
Aβ levels of the ipsilateral hemisphere were analyzed. As one PBS injected animal died, 
we were able to compare only one control with two TTR-treated females. Both TTR-treated 
animals presented reduced Aβ levels when compared to the control, being the effect more 
striking in the detergent soluble fractions (figure 17A). However, a high variability within 
the TTR treated group was observed, what could be related to the one month of age 
difference between the two animals. To clarify whether differences were related to TTR 
administration we performed Aβ immunohistochemistry in the contralateral hemispheres 
to visualize the basal levels of Aβ plaques. We observed similar differences between 
animals in the contralateral side as the ones observed in the ipsilateral side (figure 17B). 
As demonstrated in figure 16A, administrated TTR has no access to the contralateral side 
what shows that the results determined in the ipsilateral side were not related to TTR effect 
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but to an intrinsic variability in Aβ deposition between animals, which was observed even 
in animals with the same age. 
 
  
Figure 16 – Administrated TTR localizes in the hippocampus but is also retained at the site of injection. 
After intracerebral injection, labeled TTR was found in the ipsilateral hemisphere but not in the contralateral 
one (A) and also at the site of injection (B). 
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Figure 17 –AD/TTR-/- female mice present a high variability on Aβ levels and plaque burden. Half brain 
detergent soluble (A) and formic acid soluble Aβ levels (B) and representative images of Aβ plaque burden 
(C) of AD/TTR-/- female mice at different ages (15 and 16 months old) after intracerebral injection of either 
PBS (control) or TTR WT.  
Although no results were obtained in the pilot studies, we followed by performing 
the experiments to compare the effect between WT TTR and TTRH90A but with some 
modifications. Since the animals used in the pilot studies presented a very high amount of 
plaques especially localized in the superior cortex and hippocampal regions (figure 17C) 
which would interfere with the proper analysis of the results (slight variations could be 
lost), younger animals of 9 months of age were used in the following experiments. 
AD/TTR+/+ mice were also used in order to mimic the natural occurring genotype of AD 
patients. Furthermore, the hippocampus and the superior cortex were dissected for the 
determination of Aβ levels in order not to lose slight variants that might have occurred in 
these regions. 
9 months old AD/TTR+/+ female mice were injected with either TTR WT or TTR 
H90A, and Aβ levels for both detergent soluble and formic acid soluble fractions were 
analyzed by ELISA. Although the contralateral side was considered as an intrinsic control, 
non-injected mice were also used as controls. The results obtained for both brain regions 
clearly showed an enormous variation between animals within the same experimental 
group (figure 18) and also between the two hemispheres of the same animal for the control 
group (data not shown). Regarding the hippocampus, although both TTR WT and 
TTRH90A administration seemed to induce a tendency to a decrease in the detergent 
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soluble Aβ levels comparing with the controls, similar levels were observed between the 
ipsilateral and contralateral sides discarding the hypothesis of being a TTR-induced effect 
(figure 18A). For the formic acid soluble Aβ levels, variations were observed between the 
ipsilateral and contralateral sides of the control animals. Moreover, neither TTR WT nor 
TTRH90A showed an effect (figure 18B).  
Regarding the cortex, both the detergent and formic acid soluble fractions of TTR 
WT and TTR H90A treated mice showed no differences on Aβ levels between the 
contralateral and the ipsilateral side (figure 18C and 18D). Moreover, no differences were 
observed when compared to the control group.  
Both in the hippocampus and in the cortex we observed increased levels of the 
formic acid soluble Aβ fractions when compared to the detergent soluble ones, in all the 
experimental conditions. These results suggest that the brains of these animals are richer 
in plaques than in less aggregated forms. 
Since no conclusions can be taken out of TTR WT and TTR H90A administration, 
one cannot infer with certainty if TTR neuroprotective effect in AD is related to its 
proteolytic activity in vivo using this methodology. 
 
 
Figure 18 – 9 months old AD TTR+/+ female mice show a high variability on both hippocampus and 
cortex Aβ levels of after TTR treatment. Aβ levels of 9 months old AD TTR+/+ females that suffered 
intracerebral injections of either TTR WT or TTR H90A (ctrl – non-injected animals). Both the cortex and 
hippocampal Aβ levels for both detergent soluble (A and C) and formic acid soluble (B and D) fractions showed 
to be highly different between animals. Results showed as means ± SD. (Ctrl: n=2; TTR WT: n=4; TTR H90A: 
n=3) 
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Evaluation of Zebrafish as a valuable tool to test TTR proteolytic activity in 
vivo 
In order to further evaluate if TTR proteolytic activity is maintained in an in vivo 
system, 10 μM Aβ and/or 10 μM TTR WT injections in the yolk or the cell of single cell 
stage WT zebrafish embryos were performed. Two different protocols for protein 
extraction were tested but, although TTR was successfully identified (figure 19A), Aβ was 
not detected (data not shown). ELISA assay and immunohistochemistry against Aβ were 
also tested and neither of these methodologies worked (data not shown). To verify which 
Aβ concentration could be reached (in order to assure Aβ detection) without inducing an 
increase in embryo death, a viability curve was also performed, demonstrating that 
embryos were still viable at 200 µM Aβ (figure 19B). 
 
Figure 19 – TTR WT is detectable through Western blot and WT zebrafish embryos remain viable until 
200μM Aβ injection. (A) TTR is detectable through Western blot analysis after injection in the yolk of WT 
zebrafish embryos; (B) WT zebrafish embryos were injected with different Aβ concentrations both in the yolk 
(blue line) and in the cell (red line) and 500 µM Aβ showed to be the most toxic to WT zebrafish embryos via 
both type of injections. 
In the following experiments, we decided to move to a more relevant model that 
better mimic the natural occurring situation: the existence of Aβ and TTR in the brain. 
Recently, Nery et al described that intraventricular injections of Aβ were able to induce 
cognitive defects in zebrafish, proposing this model as a good platform for the study of AD 
pathology in zebrafish (Nery, Eltz et al. 2014). In order to overcome the limitations found 
regarding Aβ detection, we used the reported methodology to inject the ventricle of 24hpf 
WT zebrafish embryos with 200 µM Aβ. Although the concentration used was twenty times 
higher than the one reported in the referred paper, after western blot analysis, Aβ was still 
not detected (data not shown). Since we are able to detect TTR by western blot, in parallel, 
24hpf WT zebrafish embryos were injected in the brain ventricle with TTR-488 in order to 
verify where TTR localizes when injected in this animal model. TTR seemed to travel 
inside the embryo and accumulated in the endothelial cells (figure 20). Furthermore, no 
morphological changes were observed after intraventricular injection in any of the above 
mentioned experiments. 
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Figure 20 - TTR injected in the ventricle is mislocated into the endothelial cells. WT zebrafish embryos 
were intraventricularly injected with TTR-488 and presented a mislocation of TTR into the endothelial cells. 
We followed by using a second model where Aβ was shown to induce a striking 
effect in zebrafish. We reproduced a previous reported methodology in which zebrafish 
embryos that express GFP in the vasculature (named Veins) are maintained in PTU 
medium supplemented with 5 µM Aβ (Aβ medium) every 24h. In this study, the vasculature 
of 72hpf embryos maintained in Aβ medium is reduced (Lu, Liu et al. 2014). As seen in 
figures 21A and 21B, Aβ exposed Veins embryos showed a 2,55 fold decrease in the 
vasculature area. Furthermore, the induction of apoptosis was also tested using acridine 
orange staining but no differences between the control and the Aβ exposed Veins embryos 
were found (figure 21C). Besides the reduction of the vasculature, no other morphological 
alterations were visible. Nevertheless, these results support the use of this procedure as 
a platform for the study of TTR proteolytic activity in vivo and should be used in the future. 
 
49 
 
 
Figure 21 - Aβ exposure leads to a reduction in the area of the vasculature of Veins zebrafish embyros, 
but does not induce cell death. A and B- 72hpf Veins zebrafish embryos exposed to 5 µM soluble Aβ 
showed a 2,55 fold decrease in the area of the vasculature (p=0.0042). C - 72hpf Veins zebrafish embryos 
exposed to 5 µM soluble Aβ didn’t present apoptotic staining when comparing with the control situation. 
Statistics: Results showed as means ± SEM.  Student t-test - *p < 0.05, **p < 0.01, ***p < 0.001 
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DISCUSSION 
Aβ accumulation is considered the major pathological change in AD progression. 
In this respect, therapeutic strategies targeting Aβ degradation, by delivery of Aβ-
degrading enzymes to the brain, are emerging as a valuable option for treating AD. TTR 
is a metalloprotease described as being able to cleave the Aβ peptide (Costa, Ferreira-
da-Silva et al. 2008). Moreover, in vitro data from our group demonstrated that TTR WT, 
but not the proteolytically inactive form of the protein, is capable of interfering with Aβ 
fibrillization by both inhibiting and disrupting fibril formation (unpublished data). These 
results suggested TTR proteolysis of Aβ as a protective mechanism in AD. However this 
hypothesis based on in vitro results was lacking support from in vivo data. In this work, we 
evaluated the role of TTR proteolytic activity in AD in cell based assays, using both cell 
lines and primary neuronal cultures, and in vivo using mice and zebrafish as animal 
models. 
We started by confirming TTR cleavage of Aβ in physiological conditions by using 
N2A-APPswe cells, a CNS cell line that stably expresses APP Swedish mutation 
producing high levels of Aβ peptide. Besides further confirming TTR cleavage of Aβ, this 
cell based assay also demonstrated that TTR proteolysis contributes to Aβ clearance. 
Ongoing experiments are being currently performed to analyze the effect of TTR WT and 
TTR H90A in a reported model in which differentiated THP-1 cells incubated with Aβ 
induce the formation of congo-red positive Aβ plaques (Friedrich, Tepper et al. 2010). This 
experiment will confirm if TTR proteolytic activity is required for the clearance of higher 
aggregated Aβ species under physiological conditions. In order to access the effect of 
TTR proteolysis on Aβ-induced cytotoxicity, we used primary cultures of hippocampal 
neurons, a clinically relevant cell type in AD. We demonstrated that TTR WT was able to 
decrease Aβ oligomers-induced caspase-3 activation, while TTR H90A had no effect. 
Nevertheless, TTR WT did not promote a complete rescue of cytotoxicity. These results 
might be related with the reported low activity of the protein (Liz, Leite et al. 2012). 
Moreover, we determined that both TTR forms induced neurotoxicity in the absence of Aβ 
oligomers. These results that might result from TTR aggregation might be affecting the 
effect in the presence of Aβ oligomers. In summary, the cell based assays further 
confirmed TTR cleavage of Aβ in physiological conditions demonstrating that TTR 
proteolytic activity is required for its neuroprotective effect in AD, by degrading Aβ and 
decreasing Aβ-induced neurotoxicity. These results prompted us to analyze the effect of 
TTR proteolysis in vivo. 
To dissect the effect of TTR proteolytic activity in AD pathology in vivo, 
intracerebral unilateral administration of either TTR WT or TTR H90A were performed in 
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an AD mice model. Although we were unable to detect any effect of either TTR WT or TTR 
H90A in the levels of Aβ42 in our model, we observed a high variability between animals 
of the same experimental group and even between the two brain hemispheres of the same 
animal (in control animals). This variability was previously observed in the reported 
characterization of the model used (Oliveira, Ribeiro et al. 2011) and we consider it might 
have affected our results. Therefore, no conclusions about TTR proteolytic activity in AD 
pathology in vivo can be taken out of these experiments. Nevertheless, the lack of an 
effect induced by TTR might by related with several facts: i) low activity of the protease in 
vivo; ii) reduced amount of enzyme in affected regions; iii) a putative aggregation of TTR 
in vivo blocking its effect; and iv) high Aβ content that hamper the detection of slight 
variations.  
Previously reported studies showed that the overexpression of human TTR in AD 
mice had beneficial effects both at behavioral and biochemical levels (Buxbaum, Ye et al. 
2008). To overcome the limitations above described, AD mice overexpressig both TTR 
variants could be developed in order to study the effect of TTR proteolysis in AD pathology 
in vivo.  In this sense, the use of adeno-associated virus serotype 9 (AAV9) would be 
advised since this system was demonstrated to be successful in the transduction of the 
hippocampal tissue (Klein, Dayton et al. 2008) and has several advantages regarding 
longer term expression and safety (Simonato, Bennett et al. 2013). In these mice, the 
determination of Aβ levels and plaque burden and behavioral tests should be performed 
in order to understand if the TTR proteolytic activity influences the development of the 
disease. The use of this methodology is supported by previously a reported study for NEP 
in which NEP treated animals presented a significant decrease in congophilic-stained 
plaques in the hippocampus (Carty, Nash et al. 2013). 
Since we couldn’t take any reliable conclusions from AD mice experiments, we 
decided to use zebrafish as an in vivo system for the study of TTR proteolytic activity due 
to its unequaled advantages (Martin-Jimenez, Campanella et al. 2015). Injections of Aβ 
with or without TTR WT were performed in the yolk and cell of WT single cell stage 
zebrafish embryos. Since Aβ detection was not achieved by neither of the methods used 
(immunohistochemistry, western blot and ELISA), we decided to use a published and more 
relevant methodology in which a brain intraventricular injection of Aβ was shown to induce 
cognitive defects on zebrafish WT embryos and, although the concentration used was 
twenty times higher than the one reported, we were still unable to detect Aβ. As such, we 
did not pursue with the analysis of TTR proteolysis in the referred model. Nevertheless, in 
the referred paper, Aβ detection was not performed, being the most relevant result the 
induction of cognitive dysfunction by Aβ injection. Therefore, further studies should verify 
the induction of cognitive defects under the conditions here tested. Additionally, in order 
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to verify TTR localization after intraventricular injection, 24hpf WT zebrafish embryos were 
injected with TTR-488 using the same methodology. Labelled TTR diffused inside the 
animal and localized in the endothelial cells, what might be related to the lack of a 
functional blood-brain barrier at this stage (Fleming, Diekmann et al. 2013). 
In order to overcome the constraints faced, Veins zebrafish embryos were 
incubated with Aβ and the gut vasculature was analyzed, a model previously described 
for Aβ detrimental effects (Lu, Liu et al. 2014). Treated animals showed a significant 
decrease in the area covered by the gut vasculature when comparing with controls but no 
differences were found in the cell viability assay. These results show that the reporter line 
Veins might be a valuable tool in the study of TTR proteolytic activity in vivo. Being that, 
further studies in which this line is injected in the brain ventricle either with TTR WT or 
TTR H90A and is then submitted to Aβ exposure are currently ongoing.  
Additionaly, the development of an AD zebrafish model overexpressing either 
human TTR WT or TTRH90A would be a valuable option. Comparing with mice, zebrafish 
has great advantages: it allows generation of a sufficient number of subjects in less time 
and with less associated-costs and since it is a simpler animal model, less variants would 
interfere with the expected outcome.  Since zebrafish WT PS1 is able to cleave APPswe 
producing high amounts of Aβ42 (Leimer, Lun et al. 1999), it would be interesting to 
generate an APPswe transgenic zebrafish that expressed the mutant in the nervous 
system throughout life. To do so, the APPswe gene sequence governed by the expression 
of the HuC promoter which drives gene expression to the CNS (Higashijima, Hotta et al. 
2000) could be inserted into a Tol2 transposable element (Kawakami, Shima et al. 2000). 
After characterization of the model, this line could be crossed with TTR transgenic 
zebrafish, a line that could be generated by the same methodology, but using the FABP10 
promoter to direct gene expression into the hepatocytes (Mudbhary, Hoshida et al. 2014). 
Aβ levels, cytotoxicity and cognitive defects in this model could be addressed to further 
reinforce the data here presented for the role of TTR proteolytic activity in vivo.  
In summary, the results here presented support the importance of TTR proteolytic 
activity in a neuroprotective context. If TTR activity will be relevant for preventing the 
development of AD in vivo, the modulation of TTR proteolysis might constitute a valuable 
therapeutic strategy. 
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CHAPTER 3 
NEUROCYTOSKELETON REMODELING AS A 
CONSEQUENCE OF PROTEIN AGGREGATION 
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THEORETICAL BACKGROUND 
 Several neurodegenerative diseases occur as a consequence of the deposition 
protein aggregates. Although being a hallmark in neurodegeneration, the actual role of 
protein aggregation in disease progression remains unclear. Alzheimer’s disease (AD) 
and Parkinson’s disease (PD) are two major examples of central nervous system (CNS) 
disorders resultant from protein aggregation. AD is associated with extracellular deposits 
of amyloid-β peptide (A) in senile plaques and accumulation of hyperphosphorylated tau 
proteins in neurofibrillary tangles leading to progressive cognitive decline (Castellani, 
Rolston et al. 2010). PD is typically characterized by motor impairment, in which the key 
pathological hallmarks are the formation of cytoplasmic inclusions composed of α-
synuclein, known as Lewy Bodies, and the loss of dopaminergic neurons (Galloway, 
Mulvihill et al. 1992). In the peripheral nervous system (PNS), familial amyloid 
polyneuropathy (FAP) is a typical Portuguese case of protein aggregate-induced 
neuropathy. FAP is characterized by the deposition of insoluble mutated transthyretin 
(TTR), in the form of oligomers, aggregates and amyloid fibrils, particularly in the PNS 
(Plante-Bordeneuve and Said 2011). 
Recent studies have revealed that defects on the neuronal cytoskeleton and 
axonal transport are associated with several neurodegenerative disorders. AD represents 
the leading disease where cytoskeleton damage has been addressed mainly because of 
the involvement of tau, a microtubule stabilizer. Moreover, A oligomers have been shown 
to mediate neurotoxicity by inducing major alterations in both microtubules and actin 
dynamics (Mendoza-Naranjo, Gonzalez-Billault et al. 2007, Ramser, Gan et al. 2013, 
Pianu, Lefort et al. 2014).  
Considering the effect of A oligomers in the neuronal cytoskeleton, it would be 
important to determine whether cytoskeleton alterations induced by protein aggregates 
constitute a common pathogenic mechanism among different neurodegenerative 
disorders. In fact, cytoskeleton defects have been also suggested in PD (Cartelli, 
Casagrande et al. 2013, Hunn, Cragg et al. 2015). Although dopaminergic neurons are 
the main neuronal population affected in PD, brain immunohistochemical analyses from 
PD patients showed a reduction in hippocampal cholinergic activity and also Lewy bodies 
deposition in the basal forebrain and hippocampus (Hall, Reyes et al. 2014). In this 
respect, both monomeric and aggregated forms of α-synuclein were shown to be secreted 
by neurons (Marques and Outeiro 2012). α-synuclein secretion could explain the referred 
pathology spreading in PD, and suggest an extracellular pathologic role for α-synuclein, 
which might be related to cytoskeleton remodeling. Nevertheless, the effect of α-synuclein 
oligomers on the cytoskeleton of hippocampal neurons was not previously assessed. 
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Concerning FAP, unpublished data from our group showed that there is a disruption of the 
normal growth cone morphology of the peripheral dorsal root ganglia neurons induced by 
TTR oligomers. A recently published paper has also suggested that there is a CNS 
involvement in FAP pathology (Maia, Magalhaes et al. 2015). The report disclosed that 
patients who carry the TTR V30M mutation and had liver transplant show clinical CNS 
disturbances that might be related to TTR V30M accumulation in the CNS. However, the 
role of TTR variants in CNS neurons was still not addressed. 
In this work we aimed to characterize the effect of different prone-to-aggregate 
proteins in the neuronal cytoskeleton of a common cell type. We used as read-out the 
growth cone morphology of hippocampal neurons and the effect of the following species 
was analyzed: i) A oligomers, untreated or treated with TTR, to determine whether TTR 
reverts cytoskeleton defects induced by A oligomers; ii) α-synuclein in different 
aggregations stages and iii) TTR amyloidogenic mutants.  
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MATERIALS AND METHODS 
Preparation of protein aggregates 
Aβ oligomers were produced as referred in chapter 2, section 2. For this purpose, 
10 µM Aβ diluted in F12 medium (Lonza) was incubated for 3 days at 4ºC, pH 7. The three 
different TTR forms (WT, V30M, L55P) were produced as stated in chapter 2, section 2 
and were incubated for 2-4h at RT, pH 7 to produce aggregated forms. α-synuclein 
monomers, oligomers and fibrils were kindly provided by Dr. Hugo Vicente Miranda from 
The Chronic Diseases Research Center (Lisbon, Portugal). 
Hippocampal neurons culture 
The hippocampal neurons culture were performed as referred in chapter 2, section 
2. For the analysis of growth cone morphology, cells were plated at a density of 10000 
cells per well in coverslips previously coated with 20 µg/ml poly-L-lysine (Sigma). After 3 
DIV, cells were incubated O/N, 37ºC with the referred protein species: 10 µM Aβ 
oligomers; 5 µM of each TTR variant; 500 nM α-synuclein of each aggregated forms. 
Immunocytochemistry 
After fixation with Super Phem buffer (4% PFA, 4% sucrose (Merck), 300 mM 
PIPES (Merck), 125 mM HEPES (Sigma), 50 mM EGTA (Sigma), 10 mM magnesium 
chloride (Merck) in water)  for 15min, cells were permeabilized with 0,2% Triton X-100 
(Sigma) for 5 min at RT and were then incubated with 200 mM ammonium chloride (Merck) 
for 5 min to quench the endogenous fluorescence. Blocking buffer solution, composed of 
2% FBS (Invitrogen), 2% bovine serum albumin (Sigma) and 0,2% fish gelatin in PBS, 
was added and cells were incubated for 1h at RT. Cells were then incubated for 1h at RT 
with primary antibody mouse βIII tubulin (1:2000, Promega) in 10% blocking buffer. Cells 
were incubated with the secondary antibody anti-mouse alexa 488 (1:1000, Life 
Technologies) and phalloidin conjugated with alexa 568 (1:100, Life Technologies) in 10% 
blocking buffer. Finally, the samples were mounted in Vectashield with DAPI and images 
were captured by In Cell microscope (GE Healthcare) at 40x magnification. 
Growth cone morphology analysis 
Growth cone morphology was analyzed in over 100 polarized cells (neurons with 
a long, well-defined axon). Growth cones were divided into two classes: normal and 
dystrophic (Table 3). Also, the relative percentage of polarized cells was assessed. 
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Table 3 - Growth cone morphology is divided into two classes: normal and dystrophic. Axons are double 
labelled with phalloidin that stains F-actin (red) and with a monoclonal antibody against βIII tubulin (green). 
TYPE 
REPRESENTATIVE IMAGE DESCRIPTION 
Normal 
 
 
actin presented both filopodia 
and lamellipodia; 
MTs presented a splayed or 
bundled conformation 
Dystrophic 
 
   
total disorganization of actin 
and MTs pattern 
 
Statistical Analysis 
Results are presented as means ± SEM. All analyses were calculated with 1-way 
ANOVA test, followed by Tukey’s multiple comparison tests using GraphPad Prism 
Software: *p<0.05; **p<0.01; ***p<0.001. 
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RESULTS 
TTR WT is unable to rescue Aβ oligomers-induced cytoskeletal alterations 
in the growth cone of hippocampal neurons  
The neurotoxic effect of Aβ has been linked to alterations in the neuronal 
cytoskeleton (see chapter 1, section 3.2.1). Since dystrophic neurites are found in the 
surroundings of Aβ plaques, we decided to evaluate if Aβ oligomers (the main toxic form 
in AD) induce alterations in the growth cone morphology of hippocampal neurons. As TTR 
was suggested as a neuroprotector in AD, we also assessed if TTR WT is able to rescue 
Aβ oligomers-induced phenotype. The different categories in which growth cones of 
polarized hippocampal neurons were divided are represented in table 3.  
The percentage of polarized hippocampal neurons was unchanged after treatment 
with either Aβ oligomers or Aβ oligomers plus TTR WT, suggesting that the neurons 
maintained their natural cellular architecture (figure 22A). As expected, due to the 
described impact of Aβ oligomers on the neuronal cytoskeleton, analysis of the growth 
cone morphology of hippocampal neurons showed that Aβ oligomers promoted a 15% 
increase in the percentage of dystrophic growth cones when comparing with the control 
neurons (figure 22B). In this phenotype, the growth cone morphology was remarkably 
altered, with MTs confined to the central zone with little extension into the periphery and 
lacking the typical lamellipodial actin structures (table 3). The addition of TTR WT did not 
rescue this phenotype, showing only a 4% decrease in the percentage of dystrophic 
growth cones when comparing with Aβ oligomers condition (figure 22B).  
 
Figure 22 – Aβ oligomers alter the growth cone morphology of polarized hippocampal neurons, a 
phenotype that is not rescued by the addition of TTR WT. A - Hippocampal neurons incubated with 10µM 
Aβ oligomers alone or in the presence of 5µM TTR WT showed a similar percentage of polarized cells. B - 
Hippocampal neurons incubated with 10µM Aβ oligomers presented an increased number of dystrophic 
growth cones. However, the addition of 5µM TTR WT did not rescue this phenotype. Statistics: number of 
replicates: n=2; 1-way ANOVA test; data are mean ± SEM; *p < 0.05. 
 
 
                                                                                                                                            
62 
 
α-synuclein does not impact in the neuronal cytoskeleton remodeling 
α-synuclein has been shown to impact on the neurocytoskeleton, altering axonal 
transport and MT dynamics (see chapter 1, section 3.2.2). α-synuclein was detected in the 
extracellular environment, accumulating as LB also in the hippocampus of PD patients. In 
order to assess if α-synuclein induces the same morphological alterations as Aβ in the 
neuronal growth cone, mice hippocampal neurons were incubated either with 500 nM of 
α-synuclein monomers, oligomers or fibrils. The percentage of polarized cells was 
maintained in the three experimental conditions (figure 23A), showing that α-synuclein 
aggregated forms did not alter the overall morphology of the neurons. Concerning 
alterations in the growth cone morphology, in the three experimental conditions a slight 
increase in the percentage of dystrophic growth cones was observed, although not 
statistically significant, being that α-synuclein monomers, oligomers and fibrils increased 
the number of dystrophic growth cones by 12%, 9% and 11%, respectively, when 
comparing with control neurons (figure 23B). To further sustain the hypothesis that α-
synuclein is able to induce alterations in the growth cone morphology of hippocampal 
neurons, the number of replicates should be increased. 
 
 
Figure 23 – Growth cone morphology polarized hippocampal neurons is not altered with the addition 
of different α-synuclein species. A - The percentage of polarized cells was maintained between the different 
experimental conditions. B - Hippocampal neurons incubated with 500nM of either α-synuclein monomers, 
oligomers or fibrils presented no statistical differences in the number of dystrophic growth cones when 
comparing with the control situation. Statistics: number of replicates: n=1; 1-way ANOVA test; data are mean 
± SEM; *p < 0.05. 
Cytoskeleton organization of hippocampal neurons is not altered in the 
presence of TTR amyloidogenic mutants 
Unpublished data from our group showed that there is an alteration of the neuronal 
cytoskeleton of PNS neurons in the presence of TTR oligomers (see chapter 1, section 
3.2.3). To verify if the phenotype is maintained in CNS neurons cultures, we incubated 
mouse hippocampal neurons with either TTR WT or the amyloidogenic mutants TTR 
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V30M and TTR L55P. Although the incubation of hippocampal neurons with the different 
TTR variants did not alter the polarized structure characteristic of these neurons in culture 
(figure 24A), we hypothesized that, as previously reported for DRG neurons, TTR was 
able to induce alterations in the growth cone morphology of hippocampal neurons. We 
observed that TTR WT induced a 9% decrease, although not statistically different, in the 
number of dystrophic growth cones when comparing with the control, a phenotype that 
was not verified with the incubation with TTR V30M. The incubation with TTR L55P 
resulted in 8% decrease in the number of dystrophic growth cones showing a similar 
phenotype to TTR WT treated neurons (figure 24B). To further sustain the hypothesis that 
TTR amyloidogenic mutants are able to induce alterations in the growth cone morphology 
of hippocampal neurons, the number of replicates should be increased. 
 
 
Figure 24 – TTR WT and TTR mutants do not alter the growth cone morphology of polarized 
hippocampal neurons. A - Hippocampal neurons incubated with 5µM of either TTR WT, TTR M30 or TTR 
P55 maintained cell polarization. B – TTR WT and TTR mutants (V30M and L55P) didn’t increase the number 
of dystrophic growth cones when comparing with the control. Statistics: number of replicates: n=1; 1-way 
ANOVA test; data are mean ± SEM; *p < 0.05. 
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DISCUSSION 
Several neurodegenerative diseases occur as a consequence of the deposition of 
protein aggregates. Although being a hallmark in neurodegeneration, the actual role of 
protein aggregation in disease progression remains unclear. The neuronal cytoskeleton 
has been suggested as one of the key cellular components affected in the 
neurodegenerative processes. In this work, the effect of distinct prone-to-aggregation 
proteins, namely Aβ, α-synuclein, and TTR (the hallmarks of AD, PD and FAP, 
respectively) in the neuronal cytoskeleton of hippocampal neurons was assessed. 
Cultured hippocampal neurons have a well-organized axonal cytoskeleton organization 
presenting a growth cone with a characteristic distribution of both microtubules and actin 
filaments, what constitutes a valuable tool to analyze alterations in those cytoskeleton 
components. As such, in this work we used the growth cone morphology, by quantifying 
the percentage of dystrophic growth cones which present a complete disorganization of 
both microtubules and actin filaments, as a read-out for the effect of distinct aggregated 
species on cytoskeleton damage. We also assessed the polarization status of neurons 
under the presence of these toxic species. The percentage of polarized neurons was 
maintained in all the experimental conditions, demonstrating that the neuron preserves its 
normal architecture (the somatodendritic and axonal compartments) in the presence of 
aggregated proteins. 
The incubation of hippocampal neurons with Aβ oligomers induced an increase in 
the number of dystrophic growth cones, an expected phenotype considering the reported 
effects of Aβ oligomers in microtubule stability and on actin dynamics (Mendoza-Naranjo, 
Gonzalez-Billault et al. 2007, Ramser, Gan et al. 2013, Pianu, Lefort et al. 2014). However, 
the Aβ oligomers-induced cytoskeleton alterations were not rescued by the addition of 
TTR WT. These results in combination with the results obtained in the previous chapter of 
this thesis, suggest that TTR neuroprotective effect on AD is related to a decrease in 
Abeta-induced cytotoxicity without affecting the Aβ oligomers-induced cytoskeleton 
damage. 
We also performed preliminary experiments to address whether, similarly to Aβ 
oligomers, aggregates of α-synuclein and TTR impact on the cytoskeleton organization of 
hippocampal neurons. During the process of protein fibrillization there is the formation of 
intermediate species (oligomers and protofibrils), which are now regarded as the 
predominant neurotoxic species in both AD (see Chapter 1 section 2.4), PD (Roberts and 
Brown 2015) and FAP (Sousa, Cardoso et al. 2001). Moreover, oligomers of different 
proteins were suggested to share a common structure despite the different amino acid 
composition (Kayed, Head et al. 2003), suggesting a common mode of pathogenic activity. 
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Regarding the role of α-synuclein aggregation in the neuronal cytoskeleton, we 
observed a slight, but not statistical, increase in the number of dystrophic growth cones in 
the presence of the different species of α-synuclein, monomers, oligomers and fibrils. 
Although additional replicates of this experiment are required, the present results suggest 
that α-synuclein might impact on the cytoskeleton organization of hippocampal neurons, 
what could underlie the suggested spreading of PD pathology from dopaminergic neurons 
to the hippocampus induced by the action of secreted extracellular α-synuclein (Marques 
and Outeiro 2012). Additionally, the results with α-synuclein showed no differences 
between the different protein aggregation states what is not in accordance with the 
reported increased toxicity of the non-fibrillar species (Roberts and Brown 2015). 
Hippocampal neurons incubated either with TTR WT, TTR V30M and TTR L55P 
had no significant morphological alterations in the growth cones. Yet, a slight decrease in 
the percentage of dystrophic growth cones was visible in the presence of TTR WT, which 
was not induced by TTR V30M suggesting a loss of function of the amyloidogenic variant. 
Surprisingly, TTR L55P treated neurons showed a slight decrease in the percentage of 
dystrophic growth cones similarly to the effect induced by TTR WT. In this experiments 
TTR proteins were incubated at room temperature to induce aggregation as previously 
described (Gasperini, Hou et al. 2011). Nevertheless, the aggregation state of TTR in our 
experimental setup should be confirmed by dynamic light scattering (DLS). Although 
replicate experiments are still required, the obtained results in hippocampal neurons were 
different from the ones obtained with DRG neurons, where TTR oligomers completed alter 
the growth cone morphology of the PNS neurons. As such, it might be the case that the 
impact of TTR aggregates in the neuronal cytoskeleton might be restricted to DRG 
neurons, which are in fact the clinically relevant cell type in FAP.  
In order to be able to compare the effect of different prone-to-aggregate proteins 
in the neuronal cytoskeleton and explore the existence of common pathological 
mechanisms, hippocampal neurons should be incubated with the different protein species 
in a similar aggregation stage as assessed by DLS. After analyzing the impact of these 
proteins in the growth cone morphology, the consequences to axonal degeneration should 
also be assessed. Several parameters could be tested such as the formation of axonal 
swellings, indicators of axonal degeneration, and the impact of protein aggregates on 
microtubule stability, axonal transport and actin dynamics. These studies would help in 
the determination of common therapeutic approaches targeting the cytoskeleton that 
would be a valuable strategy for unrelated neurodegenerative disorders caused by protein 
aggregation. 
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GENERAL CONCLUSION 
In this work, we aimed to unravel the role of TTR proteolytic activity in AD both in 
vitro and in vivo. Using N2A-APPswe cell line, TTR proteolytic activity was demonstrated 
to be maintained in a physiological environment and to be involved in Aβ clearance. By 
studying Aβ oligomers-induced neurotoxicity using hippocampal neurons, we also verified 
that TTR proteolytic activity is required for its neuroprotective effect in AD. Regarding the 
in vivo studies, no conclusions could be taken out of the intracerebral injections of TTR 
performed in AD mice, since there was a high variability between the subjects. Also, using 
Veins zebrafish, that express GFP in the gut vasculate, we were able to reproduce a 
methodology previously reported that will serve in the future as a valuable tool for the 
study of TTR proteolysis in vivo. 
Regarding the second chapter of this thesis, hippocampal neurons were incubated 
with different prone-to-aggregate proteins and growth cone morphology was assessed. By 
assessing the percentage of polarized cells, we verified that neurons preserve their 
polarized architecture after treatment. Aβ oligomers increased the number of dystrophic 
growth cones, however TTR WT didn’t rescue the phenotype. We also tested α-synuclein 
and TTR amyloidogenic variants at different aggregation states and no differences were 
found between the different species and the control. Nevertheless, further studies should 
be conducted in order to unravel the precise mechanisms by which these proteins induce 
alterations in the neurocytoskeleton. The discovery of these mechanisms might open new 
insights in the development of new therapies that target the neuronal cytoskeleton in 
neurodegeneration diseases.  
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